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ABSTRACT 
 
Cigarette smoking is a worldwide health burden and ranks among the greatest public health tragedies 
causing several diseases that have already reached epidemic levels. Chronic obstructive pulmonary 
disease, heart disease and several cancers remain the main avoidable causes for premature deaths. 
Among smokers, tobacco use is largely motivated by nicotine dependence (ND). High heritability 
estimates obtained from family, twin and adoption studies clearly state the unequivocal contribution 
of genetic factors in smoking behavior. However, smoking, as any other form of substance use, is 
influenced by the complex interplay between genetic vulnerability, environmental risk factors and 
individual characteristics. Despite the high heritability estimates of ND, the underlying genetic factors 
remain largely unknown. Recent genome-wide association studies (GWAS) have identified only a 
few genetic variants contributing to this genetic liability. This work aimed to identify the contribution 
of genes and specific genetic variants predisposing individuals to smoking behavior and ND, and to 
further assess their ability to explain inter-individual differences in other smoking-related 
comorbidities and traits, such as alcohol use.   
Building upon previous linkage findings on chromosome 20, a Finnish twin family sample (N=759 
subjects from 206 families) enriched for heavy smoking was used to map susceptibility genes for 
smoking-related phenotypes. Using a dense set of markers on chromosome 20, the previous linkage 
finding (Loukola et al., 2008) was replicated with an ND measure diagnosed by the Diagnostic and 
Statistical Manual of Mental Disorders (DSM), 4th edition (DSM-IV) criteria (maximum LOD score 
3.8 on 20p11). The finding was further extended using a larger sample (N=1,302 subjects from 357 
families). Sex-stratified analyses provided a clear distinction between genetic elements on 
chromosome 20 that influence ND in adult male and female smokers. This study highlights linkage 
between chromosome 20 and ND in Finnish adult smokers. 
The same Finnish twin family sample was used in a GWAS for smoking behavior (N= 1,715). The 
data was imputed using a stochastic approach that combined the 1000 Genomes Phase I reference 
panel together with a whole genome sequence-based Finnish reference panel obtained from the 
Sequencing Initiative Suomi (SISu) project. The study yielded a genome-wide significant association 
(P=8.5x10-9) on 16p12.3 with smoking quantity defined as self-reported cigarettes smoked per day 
(CPD). Several highly correlating single nucleotide polymorphisms (SNPs) within the association 
region map to an intergenic locus near gene CLEC19A. In addition, association (P=6.6x10-8) was 
detected on 11p15.5 with nicotine withdrawal symptoms assessed by the DSM-IV criteria. The 
finding pinpointed genes AP2A2 and MUC6. These findings on chromosomes 16 and 11 highlight 
the role of neurotrophin signaling pathway in smoking behavior. 
The most robust smoking behavior locus to date has been mapped to chromosome 15q24-q25, which 
harbors a gene cluster (CHRNA5-CHRNA3-CHRNB4) encoding nicotinic acetylcholine receptor 
(nAChR) subunits α5, α3 and β4. Three of the most intensively studied SNPs on the locus were 
analyzed by combining two large and individual Finnish population-based samples, The National 
FINRISK Study and The Health 2000 Survey, into one sample (N=8,356). Using an association 
analyses approach, the study replicated an earlier finding reporting association between three distinct 
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loci on 15q25.1 and CPD (Saccone et al., 2010), and further confirmed that the alleles at this strongest 
smoking behavior locus explain approximately 1% of the variance in CPD.   
Plausible pleiotropic effects of nAChRs were examined in two studies using SNPs tagging the robust 
smoking behavior locus on chromosome 15. First, we provided novel evidence of association between 
a genetic variant on 15q25.1 and alcohol use (OR=1.15, P=7.0x10-5) in the National FINRISK Study 
and the Health 2000 Survey (N=31,812). Second, we participated in an international collaboration 
work aiming to estimate the causality between smoking and body mass index (BMI) with a Mendelian 
Randomization approach. The National FINRISK study was included in the Mendelian 
Randomization meta-analyses, which demonstrated that variants on 15q25.1 may contribute to BMI 
and the direction of the outcome is related to smoking status: never smokers are associated with higher 
BMI, whereas current smokers are associated with lower BMI.  
Taken together, these results improve our knowledge of the genetic factors affecting smoking 
behavior and ND. They also provide further evidence on the pleiotropic effects of the nAChRs. 
However, more work is required, since the genetic architecture of variants influencing smoking 
remains scarce. In addition, bigger samples and large collaborations are needed to observe the many 
small effects of yet unidentified variants affecting complex traits – the ones that our genome currently 
keeps hidden.   
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TIIVISTELMÄ 
 
Tupakoinnin terveyshaitat luovat yhden suurimmista uhkakuvista kansanterveydelle 
maailmanlaajuisesti. Keuhkoahtaumatauti, sydänsairaudet sekä useat syövät muodostavat mittavan 
osuuden tupakoinnin aiheuttamista ennaltaehkäistävistä kuolemista. Tupakointi ja sitä ylläpitävä 
nikotiiniriippuvuus ovat monitekijäisiä ilmiasuja, joihin vaikuttavat niin ympäristö, perimä kuin 
henkilön yksilölliset ominaisuudet. Perinnölliset tekijät selittävät noin puolet nikotiiniriippuvuuden 
normaalivaihtelusta, miksi onkin olennaista kartoittaa ja ymmärtää sen geneettinen tausta. Yllättäen, 
koko perimänlaajuisissa assosiaatiotutkimuksissa tähän mennessä identifioidut riskivariantit 
selittävät vain pienen osan nikotiiniriippuvuuden vaihtelusta. Tässä väitöstutkimuksessa kartoitettiin 
perimänlaajuisesti geenien sekä kirjallisuuden pohjalta valikoitujen yhden emäksen variaatioiden 
yhteyksiä tupakointikäyttäytymiseen ja nikotiiniriippuvuuteen. Tavoitteena oli selvittää 
geenivarianttien kyky selittää ihmistenvälisiä eroja niin nikotiiniriippuvuudessa kuin 
alkoholinkäytössä.  
Aikaisempiin geneettisiin kytkentätutkimuksiin pohjautuen kromosomi 20 hienokartoitettiin 
mikrosatelliittigeenimerkkien avulla suomalaisessa kaksosperheaineistossa. Aikaisempi kytkös 
nikotiiniriippuvuuden ja kromosomin välillä vahvistettiin. Lisäksi sukupuolten välillä havaittiin 
selkeä ero nikotiiniriippuvuuteen vaikuttavissa geenimerkeissä.  
Samassa suomalaisessa kaksosperheaineistossa selvitettiin koko perimänlaajuisella 
assosiaatiotutkimuksella geenivarianttien yhteyttä tupakointikäyttäytymiseen, nikotiiniriipuvuuteen 
sekä nikotiinivieroitusoireisiin. Tutkimus osoitti selkeän yhteyden kromosomin 16 geenivarianttien 
ja päivittäisen tupakkamäärän välillä. Yhteys paikannettiin lähelle geeniä CLEC19A. Kromosomin 
11 ja nikotiinivieroitusoireiden välillä havaittiin yhteys, joka paikannettiin geeneihin AP2A2 ja 
MUC6. Nämä tulokset korostavat hermostollisen kehityksen ja selviytymisen kannalta oleellisen 
neurotrofiinien viestintäketjun merkitystä tupakointikäyttäytymisen taustalla.  
Kromosomissa 15 sijaitsevien nikotiinireseptorigeenien CHRNA5, CHRNA3 ja CHRNB4 yhteyttä 
suomalaisten tupakointikäyttäytymiseen selvitettiin kolmen tunnetun geenivariantin avulla 
FINRISKI ja Terveys 2000 aineistoissa. Tutkimuksemme vahvisti aikaisemman havainnon kolmesta 
yhden emäksen variaatioista, joilla on itsenäinen yhteys päivättäiseen tupakkamäärään. Tutkimus 
varmisti vahvimman lokuksen selittävän noin yhden prosentin tupakkamäärässä havaitusta 
vaihtelusta.  
Tupakointiin ja tupakoinnista aiheutuviin terveyshaittoihin vahvasti yhdistetyn geenialueen 
mahdollisia monivaikutteisia ominaisuuksia määritettiin kahdessa eri tutkimuksessa niin ikään 
kromosomin 15 tunnettujen geenivarianttien avulla. Ensimmäisessä tutkimuksessa havaittiin uusi 
yhteys nikotiinireseptoreiden ja alkoholin käytön välillä. Toisessa tutkimuksessa arvioitiin 
tupakoinnin vaikutusta painoindeksiin. Kyseinen kausaalitutkimus oli osa laajempaa kansainvälistä 
konsortiotutkimusta. Osatyön mukaan tupakoimattomilla henkilöillä geenivariantti oli yhteydessä 
korkeampaan painoindeksiin, kun taas tupakoivilla henkilöillä sama geenimuunnos oli yhteydessä 
alhaisempaan painoindeksiin.  
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Väitöstutkimuksessa havaittujen tulosten avulla olemme saaneet lisää tietoa 
tupakointikäyttäytymiseen ja nikotiiniriippuvuuteen vaikuttavasta geneettisestä muuntelusta. 
Havaitut geenimerkit kuitenkin lisäävät perimän osuutta nikotiiniriippuvuuden selittäjänä vain vähän. 
Lisäksi tulokset auttavat ymmärtämään geenien monivaikutteisia ominaisuuksia. Erityisesti 
nikotiinireseptoreiden genomitiedon kartoittaminen voisi antaa hyödyllistä lisätietoa eri 
riippuvuuksien hoidon suunnittelussa. 
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1 INTRODUCTION 
 
Cigarette smoking remains the single major cause of avoidable global public health epidemics. 
More than five million yearly deaths can be attributed to tobacco use. It has been causally linked to 
multiple diseases and adverse health effects, including chronic obstructive pulmonary disease 
(COPD), cardiovascular disease and lung cancer, as well as several other cancers, which affect 
nearly all organs of the body (USDHHS, 2014).  
Despite the well-documented risks, the World Health Organization (WHO) has estimated that in 
2012, over 1.1 billion people smoked tobacco (WHO, 2015). The estimated worldwide prevalence 
of currently smoking adults has reached 22%, with smoking rates varying widely between countries 
(WHO, 2015). On average, smoking is still most prevalent in Europe, and least prevalent in Africa.  
Although the worldwide ratios of women-to-men smoking prevalences vary across countries, 
currently, smoking among women is less prevalent than among men. However, the estimates of 
female smoking are projected to rise in the future, especially in many low- and middle-income 
countries (Hitchman and Fong, 2011). The rise of smoking among women can be attributed to 
several factors: changes in social acceptance, women’s rising economic resources, and worryingly, 
to the tobacco industry’s marketing of cigarettes to women as a symbol of emancipation (Amos and 
Haglund, 2000). 
Marketing plans of the tobacco industry, although highly efficient, are not the sole perpetrators 
leading to the worldwide epidemic of smoking-related health consequences. Smoking is a highly 
efficient and fast form of drug use, and one force driving the behavior is nicotine dependence (ND), 
which is characterized by the persistent use of tobacco products and the emergence of withdrawal 
symptoms during abstinence (USDHHS 2014).  
Ever since the identification of nicotine as the primary psychoactive drug in tobacco smoke, with an 
addiction potential comparable to heroine, a great amount of time and effort has been spent to 
unravel the neuropharmacological and behavioral aspects of its effects. Various neurotransmitter 
systems have been linked to mediate the psychoactive and addictive nature of nicotine (Laviolette 
and van der Kooy, 2004).  
ND is a multifactorial and multidimensional phenomenon, with physiological, social, and 
psychological levels. Twin studies have established high heritability estimates, approximately 50% 
for persistent smoking (Tyndale, 2003; Hughes et al., 2006). These heritability estimates clearly 
state that genetic factors significantly contribute to the susceptibility for smoking behavior and ND. 
During the past decade, genetic studies have examined the human genome, aiming to identify 
genetic variants that would predispose us to smoking behavior. However, only a few genetic 
variants have been successfully identified, and they explain just a fraction of the variance in 
smoking behavior. This thesis focused on identifying specific genes predisposing individuals to 
smoking behavior and ND.  
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2 REVIEW OF THE LITERATURE 
 
2.1 Introduction to human genetics 
 
Inherited factors contribute in some way to nearly every human trait. Genetic factors, interacting with 
environmental and individual characteristics contribute significantly to the susceptibility of 
developing diseases which place a heavy burden on an individual as well as public health and the 
economy. Ever-evolving tools for identifying and characterizing the contribution of genetic variants 
have assisted medical research in shifting healthcare to personalized levels, since the inclusion of 
personal genomic portfolios in medical practice has become widely acknowledged as a pivotal part 
of a holistic approach in disease treatment. Since genetically inherited variation can affect how a 
person responds to drug treatments, adverse drug responses can be predicted or even prevented by 
applying the required information from personal genetic profiles of variants in genes encoding drug-
metabolizing enzymes and drug transporter proteins (Su et al., 2014). 
2.1.1 Human genome 
 
The human genome consists of 46 chromosomes, 23 inherited from a mother and 23 from a father. 
There are 22 pairs of autosomes and 2 sex chromosomes (X and Y). Each nucleus in most cells, with 
a few exceptions, for example, red blood cells, contains the complete paired set of chromosomes, 
consisting of deoxyribonucleic acid (DNA) tightly wrapped around histone proteins, referred to as 
chromatin. Each of our cells also contains varying amounts of extracellular maternally-inherited 
mitochondrial DNA, which is stored in mitochondria.  
DNA is a polymer compound made up of two complementary nucleotide strands, which are entwined 
in the shape of a double helix. Details of this double helix were first published in 1953 in the famous 
work by Watson and Crick (Watson and Crick, 1953). The building blocks of nucleotides are 
composed of deoxyribose sugar, a nitrogenous base and at least one phosphate group. Sugar and 
phosphate groups alternate to form the backbone structure for a DNA strand, and two strands are 
paired by complementary bases: adenine (A) pairs with thymine (T), and guanine (G) pairs with 
cytosine (C). Hydrogen bonds bind the complementary bases, and thus play a major role in stabilizing 
the DNA double helix shape. In 1961, less than a decade after the demonstration of DNA’s structure, 
the genetic code was cracked and resolved, showing that each codon, a triplet of bases, translates into 
a different amino acid (Crick et al., 1961).  
The human genome is made up of over 3 billion base pairs (Lander et al., 2001; Venter et al., 2001), 
and the order of them determines the meaning of our genes. Merely a small fraction, approximately 
1.2%, of the entire DNA sequence codes for exons in genes, which further code for proteins, while 
other parts of the genome are non-coding. Some of the non-coding sequences contain regulatory 
regions (i.e., instruction sites for directing gene expression). 
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Currently, the estimated number of genes in the genome is around 23,000, considerably fewer than 
initially thought in the beginning of the era of genomic discoveries. These genes, however, can be 
transcribed into multiple different proteins through alternative splicing, and they can be adapted for 
use in different biological contexts. The majority of these genes are evolutionarily conserved, which 
is a strong indicator of function, and thus suggests that they correspond to genuine proteins (Pruitt et 
al., 2009). In addition, the genome harbors non-protein coding ribonucleic acid (RNA) genes, and 
pseudogenes (Naidoo et al., 2011), which challenges the definition of a gene. A specific feature of 
these “genes” is that they lack protein-coding abilities. Nevertheless, they may have important 
regulatory roles (Poliseno, 2012; Ulitsky, 2016).  
How the human genome functions is only just beginning to be clarified. The term “functional 
element” is defined as a discrete region on the genome that encodes a defined product, like a protein, 
or a reproducible biochemical signature (e.g., a specific chromatin or transcription structure). Such 
signatures mark genomic sequences with important functions, including exons, sites of RNA 
processing (introns, sequences between exons that are cleaved from the original transcript, and 5’ and 
3’ un-translated regions), and transcriptional regulatory elements, like promoters, enhancers, 
silencers, and insulators. Although certain biochemical signatures can be associated with specific 
functions, their ultimate biological roles and functions cannot be declared, but, rather, require further 
validation (ENCODE Project Consortium, 2011). While the research community desires to elucidate 
genomic function in human biology and disease, the means for defining these DNA elements require 
combining biochemical, evolutionary and genetic approaches (Kellis et al., 2014). Challenges in 
deciphering gene functions have recently spurred novel projects for cataloging gene annotations that 
will integrate genome exploration with gene expression, epigenomic and reference panel datasets 
(Mudge and Harrow, 2016). So far, the task remains challenging. 
 
Genetic variation 
Although human genomes between any two individuals are 99.9% identical, there are forms of 
genetic variation that distinguish us from each other. Sources leading to this variation are mutations 
and recombination events. Genetic variation consists of SNPs, insertions and deletions, repeated 
sequences and chromosomal abnormalities. Although these variable sites account for only a small 
portion of the human genome, they represent the mechanism for subtle differences that are observed 
among individuals, which can contribute to variation in the development of a trait or disease. In 
addition, these sites can be used for mapping the genetic variants affecting a phenotype of interest.  
The human genome harbors several classes of repeated sequences, which can be further categorized 
based on their length. Modern genetic mapping techniques have mostly harnessed microsatellite 
markers. These are highly polymorphic repeats of 1-10 nucleotides, and the ones used in genetic 
mapping typically consist of 10-50 copies of di-, tri-, or tetranucleotide repeats. The length of repeat 
sequences ranges from tens to hundreds of base pairs (bps), and because they are flanked by unique 
DNA sequences, they are easily amplified by polymerase chain reaction (PCR). One advantage of 
microsatellites is the large number of alleles (variant forms of a gene), resulting in a high number of 
different genotypes (each consisting of two alleles, one inherited from a mother and the other from a 
father, at each genetic loci).
Review of the literature 
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The most common type of genetic variation is a single nucleotide polymorphism (SNP), which is a 
variation in a single base. Because of the diploid nature of the human genome, a majority of the SNPs 
have two alleles. As an example, a SNP with alleles C and A can be present in a certain population 
with allele frequencies 15% and 85%, respectively. In this example, C is a minor allele at that 
particular locus, with a minor allele frequency (MAF) of 15%. The HapMap Project has estimated 
that, in the human population, about 10 million sites vary so that the alleles are observed in the 
population with at least 1% frequency (The International HapMap Consortium, 2003). The majority 
of these SNPs are common variants, meaning that their allele frequency in a population is at least 5%. 
The rest of the 10 million SNPs are low-frequency variants (MAF 1% < 5%). In addition, the human 
genome harbors large numbers of rare SNPs, with an MAF of less than 1%. The Exome Aggregation 
Consortium (ExAC) (http://exac.broadinstitute.org/) has proposed the following evidence-based 
MAF categorization: common variants MAF > 10%, low-frequency variants 1-10%, rare variants 0.1-
1.0%, and ultra-rare variants < 0.1% (Lek et al., 2016).  
Depending on their locations, SNPs have varying effects on the phenotype. In the coding region, 
SNPs that alter the amino acid sequence, causing a missense mutation, may alter the final protein 
product to varying degrees. Intergenic regions (sequences between two genes) contain regulatory 
sites, where a SNP can have a regulatory effect on protein synthesis. SNPs are not equally distributed 
within the genome, but are more frequent within the non-coding, intergenic regions, compared to 
coding regions. In general, SNPs are located in sites where natural selection fixes the allele that 
contributes to the most favorable genetic adaptation at that particular moment in time. Other factors, 
like genetic recombination and mutation rates, can affect the SNP density as well. Genetic variation 
varies between populations, a SNP that is common in one population or geographical group can be 
rarer in another. 
 
Linkage disequilibrium 
Linkage disequilibrium (LD) refers to the occurrence of non-random association between two alleles 
at different loci. Usually, when a chromosome pair separates during meiosis, cross-over events, where 
two homologous chromosomes exchange genetic material, occur at various points resulting in 
recombinant daughter chromosomes that differ from the parental ones. Some regions are more prone 
to recombination than others, which is why they are referred to as recombination hotspots. In these 
regions, LD is smaller, whereas, the regions with little recombination have larger LD. Regions with 
LD patterns are usually described as haplotype blocks, which can be used further for SNP selection 
in gene mapping studies. Since a haplotype block harbors SNPs which are in high LD with each other, 
sometimes only one tagging SNP is adequate to capture the entire genetic variation within that region, 
thus lowering genotyping expenses and providing a means to map the genome more thoroughly. In 
addition, haplotype blocks provide an essential advantage for successive gene mapping in association 
analysis, as a majority of the observed genome-wide association study (GWAS) signals are functions 
of LD between the measured marker and the causal locus. For the same reason, however, mapping 
the correct causal gene variant remains challenging. 
Some haplotypes clearly vary between populations, whereas some are amazingly similar (Rosenberg 
et al., 2002; Gabriel et al., 2002), which reflects both the immigration history of humans and 
geographic regions of different populations (Malaspinas et al., 2016; Mallick et al., 2016, Pagani et
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al., 2016). The greatest genetic variation has been observed in Africa, home of the Cradle of 
Humankind, and the diversity of haplotypes has been observed to decrease as distance from its origin 
increases (Conrad et al., 2006). This diversity needs to be acknowledged and thoroughly considered 
in all international gene mapping collaborations. 
 
Reference of the human DNA sequence 
The first draft of the human genome was published in 2000 (Lander et al., 2001, Venter et al., 2001), 
and the final draft in 2003 (International Human Genome Sequencing Consortium 2004). Building 
upon the known human genome, the International HapMap Project (http://hapmap.nci.nlm.nih.gov/) 
was launched in 2002, aiming to describe common patterns of human genetic variation that are 
involved in human health and disease (The International HapMap Consortium, 2003).  
The publicly available human reference sequence, combined with high-throughput genotyping and 
sequencing technologies, have initiated several large-scale international projects to map the human 
genetic variation in diverse populations. One of them, the 1000 Genomes Project 
(http://www.internationalgenome.org/), set out to find most of the genetic variants in the genome, and 
after completion in 2015, has provided a benchmark for surveys of human genetic variation by 
enabling more accurate array designs and genotype imputation. The third phase of the project 
reconstructed the genomes of 2,504 individuals from 26 populations (1000 Genomes Project 
Consortium, 2015), and the reference panel includes > 99% of SNP variants with a frequency of > 
1%. A more recent catalogue of human genetic diversity, ExAC, has provided the largest open access 
catalogue so far of variation in human protein-coding regions including 60,706 individuals in the 
study (Lek et al., 2016). The scale of this catalogue offers much anticipated insight into rare genetic 
variation across populations. In addition, another large-scale novel human reference panel has been 
constructed by the Haplotype Reference Consortium (HRC) (http://www.haplotype-reference-
consortium.org/) including a total of 64,976 human haplotypes of purely European descent, and aims 
to increase the imputation accuracy of SNPs with MAFs as low as 0.1%, and helps to discover 
plausible causal loci for common diseases (McCarthy et al., 2016). In addition, an entirely population-
based reference panel has been generated for a Finnish genome. As an advantage, it has been shown 
to increase imputation accuracy of rare and low-frequency variants in Finnish study cohorts (Surakka 
et al., 2016). Currently, the reference panel comprises 4,932 Finnish high-pass whole-exome 
sequences and 1,941 Finnish low-pass whole-genome sequences (Surakka et al., 2016).  
In order to increase our understanding of the genome and how it is regulated and expressed in different 
species and between individuals, novel technologies have been developed. Using a novel gene editing 
tool based on bacteria Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) -
associated protein-9 nuclease (Cas9), a recent study has provided insight into the origins of 
evolutionary adaptations (Nakamura et al., 2016). The overall function of the genome, which has 
remained mostly a mystery to scientists for over a decade, is finally starting to reveal its secrets. 
All of these projects have contributed substantially to human genomics by more precisely and densely 
mapping the sequence and by giving insight into the functional complexity of the genome. These 
advances have directed the entire scientific quest toward an era of personal genomic sequencing and 
personalized medicine (Naidoo et al., 2011). 
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Imputation 
The cost for large-scale whole-genome sequencing remains high, even though the prices have 
declined considerably during the past couple of years due to dramatic development in the sequencing 
technology (Metzker, 2010). The commercially available genotyping chips only contain some 
hundred thousand tagging SNPs, variants which are adequate to capture the entire genetic variation 
within one’s specific haplotype block. As it is uncertain whether a SNP on a genotyping chip is a true 
causal variant, the missing genotypes are imputed to the data utilizing existing catalogues of human 
genetic variation. The catalogues offer constantly updated reference panels for use, such as the 1000 
Genomes Phase I reference panel (The 1000 Genomes Project Consortium, 2012), the 1000 Genomes 
Phase III reference panel (The 1000 Genomes Project Consortium, 2015), the HRC reference panel 
(McCarthy et al., 2016), and the Finnish population-based reference panel provided by the 
Sequencing Initiative Suomi (SISu) project (www.sisuproject.fi). 
In imputation, missing genotypes are predicted based on the observed genotypes on a reference panel. 
The race for developing more accurate imputation reference panels has already yielded impressive 
results because the accuracy has improved substantially, owing to the increased numbers of whole-
genome and whole-exome sequenced genomes included in the panels. The greatest advantage of 
imputation is its ability to add the coverage of genetic data without increasing the costs. As an 
example, the 1000 Genomes Phase III reference panel increases the number of variants from ~500,000 
SNPs detected by genotyping chips to up to ~36,000,000 genetic variants. 
2.1.2 Determining the genetic component of a trait  
  
Estimating heritability 
It has been suggested that inherited factors contribute to nearly every human trait and condition. But 
how do we know that? The roots can be tracked to the time of the discovery of genetics. Although 
the word genetics was devised as late as 1905, the history of genetics reaches as far back as the work 
of the Augustinian friar Gregor Mendel, who perceived the basic laws of genetic inheritance in his 
studies with pea plants in the 1860s.  
To determine whether a trait of interest is inherited from parents to offspring, family studies estimate 
the possibly elevated risk for siblings and relatives of an affected individual to manifest the same 
condition. These family studies assess whether the risk is higher than in the general population. 
Importantly, family studies do not reveal the mechanism behind the familial aggregation, which can 
be environmental or genetic factors, or both. Twin and adoption studies play a central role in 
elucidating the genetic component. In principle, the concordance rate of a trait is calculated between 
monozygotic (MZ) twins and further compared with the concordance rate calculated between 
dizygotic (DZ) twins. This produces an estimate of the proportion of the phenotype affected by 
genetic variation (Boomsma et al., 2002), in other words, it estimates the heritability of the trait. 
Narrow-sense heritability, h2, refers to the portion of phenotypic variance in a population attributed 
by additive genetic factors (Hindorff et al., 2009).
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Narrow-sense heritability can be estimated from genome-wide SNPs genotyped in unrelated 
individuals. Owing to the easy access and feasibility of the data, this method has several advantages 
over the traditional pedigree-based one. Using this approach, it has been estimated that approximately 
half of the heritability of human height can be attributed to ~300,000 common SNPs (Yang et al., 
2010). However, merely 5-10% of the variance in height is explained by genome-wide significant 
common SNPs that exceed the significance level of 5x10-8 (Speed et al., 2012), and the method is 
sensitive to uneven LD between SNPs; high LD regions that harbor causal variants can overestimate 
the contribution of genetic variants to heritability, whereas regions of low LD may underestimate the 
explained contribution (Speed et al., 2012). A method of modified kinship matrix that weighs SNPs 
according to their local LD has been proposed to overcome the bias (Speed et al., 2012). Lately, a 
novel heritability estimation tool, linkage disequilibrium score regression has been developed (Bulik-
Sullivan et al., 2015) to utilize summary statistics from GWAS and to estimate heritability and genetic 
correlations from several meta-analyses (Zheng et al., 2017; Anttila et al., 2016). 
Heritability estimates can be affected by variations observed in the environment and allele 
frequencies. Hence, heritability estimates cannot be generalized to all populations, but they are rather 
population and sample specific. In addition, the heritability of a disorder or trait is not constant over 
time, since the environmental and genetic effects can change (Visscher et al., 2008).  
 
Complex disease genetics 
A small proportion of human traits and diseases are caused by mutations in a single gene, such as 
phenylketonuria and cystic fibrosis, and these are referred to as Mendelian disorders. They are mostly 
rare, whereas common traits and diseases, having the highest impact on public health, such as obesity 
and type II diabetes, are caused by several genetic variants together with an environment (Botstein 
and Risch, 2003; Gibson, 2012). Common disorders are also referred to as complex disorders. In 
general, these diseases are heritable in several dimensions, meaning that several genes together with 
an environment and lifestyle, which is strongly affected by the environment, all contribute to the 
disease onset. In these disorders, genetic variants individually increase the disease risk only a little, 
but together with other genetic risk variants and the environmental factors, they increase the chance 
of phenotypic heterogeneity and further the risk for inducing a disorder. For most disorders and traits, 
the majority of the risk factors, especially genetic risk variants, are unknown and yet to be discovered.  
In addition, for some complex human traits and diseases the underlying genetic variants overlap. A 
phenomenon influencing that shared genetic predisposition is pleiotropy. In pleiotropy, one genetic 
variant influences two or more seemingly distinct and unrelated phenotypic traits simultaneously, and 
may induce a wide range of symptoms. A way of exploring pleiotropy is to calculate LD-score 
regression using summary statistics. As an example, a recent study utilizing this heritability-based 
method quantified the extent of shared genetic contributions across 23 brain disorders (N=842,820), 
and highlighted the importance of common genetic variation as a risk for brain disorders. Further, it 
demonstrated the potential of heritability-based methods for providing a more comprehensive view 
of the complex genetic architecture of brain phenotypes (Anttila et al., 2016). 
In addition, epigenetics underlines the complexity of genetics. It refers to changes in the genome that 
affect gene expression and function. Currently, it has been acknowledged that genes or environmental
Review of the literature 
 
 
22 
   
 
exposures alone are hardly sufficient to completely explain a disease process, but instead they are 
components of a larger complex molecular system that, in combination, results in a phenotype. 
Epigenetics, being an integral component of this molecular system, may play a mechanistic role in 
the formulation of a trait or disease (Ladd-Acosta and Fallin, 2016). Incorporation of epigenetics into 
the field of epidemiology is likely to help distinguish biological mechanisms for disease. 
 
Mendelian randomization 
One of the fundamental public health improvement strategies is to identify environmentally 
modifiable factors that causally influence disease risk. In general, observational epidemiological 
studies are, however, plagued by their inability to reliably identify such causal association, since 
conventional genetic epidemiological association methods are affected by reverse causation and 
confounding (Smith, 2010). A way to overcome this would be to set up a randomized controlled trial, 
which, unfortunately, is limited in many cases by ethical permissions and practice (Latvala and 
Ollikainen, 2016). On the other hand, Mendelian Randomization, which has been created to model 
the random assortment of genes from parents to offspring during meiosis, provides one method for 
assessing the causal nature of environmental exposures (Davey Smith and Ebrahim, 2003).  
In the method, association between a disease and a polymorphism that mimics the biological link 
between a proposed exposure and disease is not generally infringed upon by reverse causation or 
confounding, which can skew the interpretations of conventional observational studies (Davey Smith 
and Ebrahim, 2003). Therefore, Mendelian Randomization offers an alternative method for 
experimental studies, and utilizes genetic variants as proxy measures of exposure, and it can further 
contribute to strengthening causal inference (Smith, 2010). Still, not even this approach for 
determining the genetic component of a trait remains flawless, as factors such as LD, pleiotropy and 
population stratification may distort Mendelian Randomization studies (Gage et al., 2013).  
Mendelian Randomization is based on a notion that, if X affects Y, factors affecting X must also have 
an effect on Y. A genetic variant Z that is known to associate with X is utilized as an instrument to 
investigate the causal nature of the association between X and Y (Latvala and Ollikainen, 2016). 
Causal inferences drawn from Mendelian Randomization studies are only valid if the rather strict 
assumptions of the method are met. According to these assumptions, the genetic instrument Z must 
be reliably associated with the exposure X, the genetic instrument Z must not be associated with the 
confounding factors U, and lastly, the genetic instrument Z should only be related to the outcome Y 
through its association with the exposure X (Lawlor et al., 2008). Figure 1 demonstrates the 
mechanism involved in the Mendelian Randomization method.
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Figure 1. The basic instrumental variables model for Mendelian 
Randomization. Z, instrumental variable; X, modifiable variable; Y, outcome 
of interest; U, unmeasured confounders. (Adapted from Lawlor et al., 
2008). 
 
2.1.3 Genetic mapping: methods for gene localization 
 
Genetic mapping aims to identify a gene or genes that increase the risk for a disease or trait of interest. 
The means for gene mapping largely involve estimations of correlation between a phenotype, a 
measurable feature one expresses, and genotypes assessed as genetic markers. The optimal gene 
mapping strategy depends on the underlying genetic architecture of the trait of interest.  
Since rare variants are generally family-specific, they can be identified through linkage analysis, 
which investigates the co-segregation of chromosomal loci with the trait within families. Ideally, 
linkage analyses are conducted in large multi-generation families with multiple affected individuals, 
which provide higher statistical power to detect the signals. On the other hand, if the trait is thought 
to be caused by common variants, association analysis provides more power to identify genetic risk 
variants. Although association analysis can also be performed in families, the commonly adapted 
study design utilizes large case-control cohorts, which are easier to collect than large pedigrees, 
especially when the phenotype of interest manifests with a late age of onset, in which case the parents 
of index cases might not be available for the study. Both linkage and association analyses can be 
utilized to map the genetic contribution of a trait in two distinct settings: targeted candidate gene and 
genome-wide (i.e., hypothesis-free) approaches. 
Hypothesis-free approaches do not require any previous biological knowledge of the modes of 
inheritance to detect genetic association. Whereas, candidate gene-based models require an a priori 
presumption of the gene of interest, derived either from previous studies highlighting genomic 
regions, or from an established function in a biological process or pathway connected to the 
phenotype of interest. Despite the differences between these two approaches, both have contributed 
to and increased our knowledge of the genetics of both Mendelian disorders and complex traits and 
diseases.  
 
Linkage analysis 
Linkage analysis is a powerful tool aimed to detect the chromosomal location of disease genes. 
Simply, it is based on the observation that genes that reside physically close on a chromosome remain 
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linked during meiosis (Pulst, 1999). For several years during the late twentieth century, linkage 
analysis was the predominant statistical genetic mapping approach for Mendelian and complex traits 
with familial assembly. The aim of linkage analysis is to localize a chromosomal region that co-
segregates with the disease within a pedigree. In other words, the analysis examines whether genetic 
markers within a distinct chromosomal region are inherited with a trait of interest more often than 
would be expected by chance.  
During meiosis, recombination events generate a new combination of alleles in each generation, thus 
playing a significant role in genetic diversity. Genetic markers can be used to distinguish which 
chromosomal segments have been inherited from each parent. The probability for recombination to 
occur between two loci in the genome, the recombination fraction (θ), is related to their physical 
distance: θ=0 corresponds to the two loci co-segregating together, whereas θ=0.5 corresponds to 
independent segregation. The closer the two loci are located to each other, the more likely they co-
segregate during meiosis. Linkage analysis tests whether θ between a genetic marker with a known 
position and a locus influencing the trait of interest differs significantly from 0.5. If the θ between 
two loci is less than 0.5, they are said to be linked. A measure for estimating the likelihood of linkage 
is expressed as a logarithm-of-odds (LOD) score, which is utilized to approximate the likelihood of 
co-segregation of a genetic marker with the trait of interest compared with the hypothesis of 
individual segregation (Morton, 1955). The LOD score (Z) is the logarithm base 10 of the ratio of 
two likelihoods, and expression of the likelihood as a logarithm allows for the summation of 
likelihoods observed in different pedigrees: 
 
Z(θ) = log10 
????
???????? 
 
where L is the likelihood, θ the recombination fraction (estimated from the data), and θ = 0.5 
represents the null hypothesis that the two loci are unlinked (Ott, 1974; Ott, 1989).  
A LOD score higher than 3.0 is generally accepted as evidence for linkage (Pulst, 1999), and it 
corresponds to a point-wise significance of p=1x10-4, which, on average, is regarded as significant. 
However, this assumption is applicable only to monogenic traits, whereas, the significance of a LOD 
score for a complex trait is more ambiguous (Lander and Kruglyak, 1995). To obtain a genome-wide 
significance level of 5%, corresponding to a point-wise significance of p=1x10-5, the LOD score 
needs to be raised to 3.3 (Lander and Kruglyak, 1995). LOD scores can be calculated between two 
loci (one marker locus and the unknown disease locus) at a time (single-point linkage analysis, also 
called two-point analysis), and maximum likelihood estimates can be calculated for multiple loci at 
a time (multi-point linkage analysis).  
Linkage analysis can be applied to at least two distinct study settings. In parametric linkage analysis, 
the genetic model for the disease or trait of interest must be specified, and the expected causative 
variant frequency, penetrance and phenocopy rate need to be estimated in advance. Unlike in 
monogenic diseases, these factors cannot usually be estimated precisely for complex traits. These 
prerequisites can be overcome by non-parametric linkage analysis, which does not make any 
assumptions about the disease model (Goring & Terwilliger, 2000). However, complex traits with 
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ambiguous inheritance models can cause challenges in the positional mapping, since the location of 
the linkage signal is inclined to fluctuate (Altmuller et al., 2001, Roberts et al., 1999). 
Linkage methods are particularly powerful for detection of variants with a large effect size, which 
almost always are rare in the population. The power to detect such loci using linkage methods can be 
enhanced by ascertaining families with aggregation of the trait of interest (i.e., “loading” the sample 
with the trait of interest). For example, the BRCA1 and BRCA2 genes underlying breast cancer have 
been mapped utilizing linkage studies of families specifically selected for strong aggregation of the 
disease (Bailey-Wilson and Wilson, 2011). 
 
Association analysis 
In association analysis, genetic effects of the trait of interest are examined by comparing allele 
frequencies. In general, association analysis calculates whether a marker allele is more frequent 
among affected individuals, who manifest the trait of interest, than would be expected by chance. The 
magnitude of the effect between cases and controls can be ascertained using a Chi-square test with 
one degree of freedom, or logistic regression. The latter allows the inclusion of several confounding 
factors as covariates, which need to be considered in complex trait research. Association analyses can 
also be used for estimating genetic effects for quantitative traits (such as smoking quantity and body 
mass index (BMI)) using linear regression. Association analysis is particularly suitable for detecting 
common variants in large samples.  
 
Genome-wide approaches for gene mapping 
Where candidate gene studies require an a priori knowledge of the targeted gene, genome-wide 
studies provide a hypothesis-free approach. Both linkage and association analyses can be utilized in 
a genome-wide approach. A genome-wide setting provides a suitable platform for scanning the entire 
genome before fine-mapping the highlighted regions and teasing out the possible causal locus in the 
following studies.  
Within the past decade, GWAS have been widely used for mapping common genetic variants for 
complex traits. They test associations between common genetic variants and phenotypic variation in 
a trait of interest utilizing hundreds of thousands of genotyped, or millions of imputed, variants across 
the genome. The number of SNPs analyzed using GWAS has expanded since the first conducted 
GWASs utilizing SNP chips of approximately 100,000-250,000 variants (Klein et al., 2005; 
Maraganore et al., 2005) to millions due to denser arrays and evolving imputation methodology. 
While the quality and accuracy of imputation have improved due to more accurate reference panels, 
GWAS methods have been extended to include low-frequency and rare genetic variants as well. As 
of April 2017, the GWAS Catalogue contains 2,854 publications and 33,674 SNP-trait associations 
(http://www.ebi.ac.uk/gwas/).  
Due to multiple testing, the likelihood for type I errors, increases. In statistical hypothesis testing, a 
type I error is the incorrect rejection of a true null hypothesis (i.e., detection of an effect that is not 
present: false positive), while a type II error is incorrectly retaining a false null hypothesis, and the 
analysis fails to detect an effect that is present (false negative). To account for multiple testing, a
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Bonferroni correction with its stringent threshold for statistical significance, 5x10-8, which corrects 
for approximately 1 million independent tests, has been applied as a standard rule for interpreting 
GWAS results. Other ways to account for multiple testing include the false discovery rate (FDR) 
correction (Benjamini et al., 2001) and permutation testing (Sham and Purcell, 2014). FDR 
specifically calls for controlling the expected proportion of falsely-rejected hypotheses, thus 
providing less stringent control on type I errors and greater power, at the cost of an increased rate of 
type I errors. The permutation procedure is a robust but computationally rather intensive alternative 
to calculate an empirically adjusted p-value.   
In the category of common variants, association analyses have clearly excelled at linkage analyses. 
However, an emerging view states that rare variants could explain a substantial proportion of complex 
human traits and diseases (McClellan and King, 2010). Hence, the availability of whole-exome 
sequence (WES) and whole-genome sequence (WGS) data has once again raised the value of linkage 
analysis as a powerful method for detecting those rare genetic variants, which could play even more 
important roles in the disease etiology than initially estimated (Ott et al. 2015). The high cost of 
sequencing has been one of the key factors preventing large-scale genome-wide linkage studies. 
Along with the decreasing cost of sequencing, it will become plausible and even advantageous to 
have WGS data from large pedigrees of informative phenotype carriers, and to perform large-scale 
genome-wide linkage analysis (Ott et al., 2015). However, this approach requires bioinformatics tools 
and a computational environment which are efficient enough for such enormous data and capable of 
performing analyses in a reasonable timeframe. 
 
Meta-analysis 
Meta-analysis can be utilized to increase the power to detect SNP association or linkage, since it 
summarizes the results from several carefully harmonized studies (Evangelou and Ioannidis, 2013). 
Thus, the same imputation reference panel is required from all eligible GWAS cohorts. In meta-
analysis, effect sizes from different data sets can be pooled with either fixed or random effects model. 
A fixed effects model assumes a common genetic effect through all data sets, and further explains 
any observed difference by chance alone. In a random effects model, the genetic effects are assumed 
to be different in all data sets (Ioannidis et al., 2009). 
 
Exploring the functional potential of genetic variants 
In order to infer the functional potential of the SNPs highlighted in a study, the analyses can be 
followed up by annotating the expression quantitative trait loci (eQTL) and methylation quantitative 
trait loci (meQTL) that are associated with the SNPs. eQTL refers to a SNP that has been associated 
with the expression of a local gene (cis-eQTL) or even a distant gene (trans-eQTL). Likewise, 
meQTL refers to a SNP that has been associated with methylation levels in cis or trans. eQTLs and 
meQTLs may provide a warranted means to explain the substantial inter-individual variance observed 
in traits that are not explained by the associated genetic variants.
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2.1.4 Hiding heritability 
 
The validity of the initial common disease–common variant model has been challenged by the 
existence of “missing heritability” (Manolio et al., 2009; Clarke and Cooper, 2010, Lander, 2011). It 
is evident that only a small portion of the heritability of a phenotype can be explained by common 
variants, individually or in combination. Several explanations for this phenomenon have been 
suggested. First, large numbers of variants with small effects are still to be highlighted, since the 
sample sizes in a majority of the GWASs are limited, and due to the stringent statistical thresholds 
imposed to ensure reproducibility (Lander, 2011). Second, limited sample sizes cause challenges in 
genotype calling, since rare variants as well as structural variants, which both could have large effects 
on the trait in question, are poorly detected (Manolio et al., 2009). Third, GWASs have limited power 
to detect gene–gene and gene–environment interactions (Manolio et al., 2009). Last, the current 
GWAS methodology has inadequate means for detecting shared environment effects among relatives 
(Manolio et al., 2009). On the other hand, as traits and diseases clearly run within families, the current 
methodology for mapping them on the genome might simply be inadequate. Thus, the missing 
heritability could merely be hiding.   
At the same time, some of the hiding heritability may merely be an illusion. Since the estimates of 
heritability are inferred from additive genetic effects in epidemiological data, these estimates may be 
inflated by contributions of genetic interactions and gene-by-environment interactions, which are not 
accounted for in the estimations (Lander, 2011). For example, heritability estimates conducted via 
twin models do not account for shared environment, which might skew the numbers upward (Zaitlen 
et al., 2013). Also, the ExAC project has demonstrated that a surprisingly high portion of causal 
variants originally linked to rare Mendelian diseases are missclassifications in the literature and/or in 
databases (Lek et al., 2016), and this notion may provide novel insight into the estimation of hidden 
heritability. 
2.1.5 Finnish population history and disease heritage 
 
The Finnish population is one of the best-studied genetic isolates (de la Chapelle, 1993; Peltonen et 
al., 1999). Migration waves occurring some 4000 and 2000 years ago, arriving from east and south, 
respectively, have had a considerable effect on the Finnish gene pool. Both the paternally inherited 
Y chromosome and maternally inherited mitochondrial DNA show reduced genetic diversity 
compared to other populations (Sajantila et al., 1996). In detail, genetic evidence from phylogenetic 
analysis of Y chromosome haplotypes supports the theory of a dual origin of Finns, and reveals 
dramatic differences in Y haplotype variation between eastern and western Finland (Kittles et al., 
1998). Evidence suggests that relatively few numbers of men and women have truly contributed to 
the genetic lineages that have been passed on and selected into the current generations of the Finnish 
population (Sajantila et al., 1996). 
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Reasons for this isolation can be described with geographical and geopolitical factors – being located 
between Sweden and Russia, two areas of distinct cultures, languages, and religion. In isolation, 
forces like founder effects, genetic drift, and genetic bottlenecks have shaped the genetic material in 
the Finnish gene pool, reducing the diversity. Ultimately, the Finnish population has expanded 
rapidly, mostly due to population growth, with relatively little external migration, creating regional 
sub-isolates as well (Peltonen et al., 1999).  
Owing to this population history, Finland has its own unique diseases, referred to as Finnish Disease 
Heritage, which comprises altogether 36 monogenic disorders, that are more prevalent in Finland 
compared to the rest of the world (Norio, 2003a; Norio, 2003b, Norio, 2003c). While the frequency 
of some rare disorders has increased in the Finnish population due to reduced genetic diversity, for 
the same reason, some genetic variants predisposing one to certain diseases common in other 
populations (e.g., phenylketonuria and cystic fibrosis) are almost non-existent in Finland (Peltonen 
et al., 1999).  
This genetic isolate has been advantageous in the process of mapping rare Mendelian genes (Peltonen 
et al., 2000). Using modern high-throughput exome sequencing technology, the allelic architecture 
of the Finnish population has also already revealed a significant enrichment of low-frequency (MAF 
0.5-5%) loss-of-function variants in complex disorders (Lim et al., 2014). The SISu project, which 
combines nationwide health records with WES and WGS data, has also demonstrated a clear 
distinction between Finnish and non-Finnish European genome sequences (Lim et al., 2014), and 
indicated a clear need for a population-specific imputation reference panel for Finnish samples.  
 
 
 
2.2 Smoking behavior and nicotine dependence 
 
2.2.1 Life course of smoking behavior 
 
Cigarette smoking is a complex behavior that includes several stages such as initiation, regular use, 
development of tolerance, dependence, cessation and relapse (Malaiyandi et al., 2005; Mayhew et al., 
2000). 
Several factors affect the probability of smoking initiation. A simplified list of these factors includes 
socioeconomic status, peer support and pressure, personality, cognitive factors, family background, 
gender, ethnicity, and previous substance use (Conrad et al., 1992; Buller et al., 2003; Mercken et al., 
2009). The average age of onset of regular smoking is approximately 16 years (Filippidis et al., 2015). 
This age is a significant factor in predicting continued smoking behavior, and predicts difficulties in 
quitting smoking compared to those who have initiated smoking at a later age (Khuder et al., 1999). 
Consequently, an early onset of smoking is associated with substance use later in life (Siqueira and 
Brook, 2003), and the development of substance use disorders (Lewinsohn et al., 1999), and even 
earlier onset of depression and/or anxiety disorders (Jamal et al., 2011). In addition, early-onset 
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smoking is a strong predictor associated with adverse smoking-related health consequences, such as 
the development of peripheral artery disease (Planas et al., 2002), and the risk of lung cancer (Hara 
et al., 2010). 
Repeated exposure to nicotine causes neuroadaptation (i.e., tolerance) (Wang and Sun, 2005). As the 
tolerance develops, the number of nicotinic acetylcholine receptor (nAChR) binding sites in the brain 
increases, likely due to a response to nicotine-mediated receptor desensitization (Govind et al., 2009). 
Receptor desensitization refers to the ligand-induced closure and unresponsiveness of the receptor, 
and is suggested to mediate the development of tolerance and dependence. The symptoms of 
withdrawal and craving emerge in smokers during a period of abstinence, such as night-time sleep, 
when the receptors begin to respond again (Dani and Harris, 2005). Self-administered nicotine intake 
alleviates the unpleasant symptoms related to withdrawal and craving (described in more detail in 
subsection 2.2.5), because nicotine re-binds to the nAChRs. Subsequently, by sustaining sufficient 
levels of nicotine in the plasma to prevent withdrawal symptoms, smokers sense rewarding effects 
through the dopaminergic system (Balfour, 2004).  
The development and maintenance of ND is mediated, at least in part, by neurobiological effects of 
nicotine and neuroadaptive changes with chronic nicotine exposure (Nestler, 2005). The α4β2 
receptors are the most widely expressed nAChRs in the brain, with a high binding affinity for nicotine. 
In addition, these receptors are extensively connected to dopamine (DA) and gamma-aminobutyric 
acid (GABA) neurons in the brain’s ventral tegmental area. Nicotine stimulates DA neurons directly 
via α4β2 nAChRs, and indirectly by activating excitatory glutamate neurons via α7 nAChRs (Nestler, 
2005). These effects further enhance the DA-mediated learning processes that sustain nicotine self-
administration and tighten the circle of dependence (Laviolette and van der Kooy, 2004). 
Conditioning is a primitive form of learning, and it plays a central role in drug addictions. While the 
neurobiological processes, such as neuroadaptation to nicotine exposure, reinforce the route to ND, 
at the same time, the smoker begins to associate certain moods, places, situations and environments 
with the rewarding effect obtained from smoking (Benowitz, 2009). Animal studies have suggested 
that exposure to nicotine increases the behavioral control of conditioned stimuli, which could further 
contribute to the compulsive dimensions of smoking behavior (Olausson et al., 2004). Repeated 
exposure to smoking in the same situations causes them to become efficient cues for the urge to 
smoke. Overall, conditioning and neurobiological responses to nicotine in combination enhance the 
development of ND and maintain smoking behavior (Benowitz, 2009). 
Smoking cessation causes the emergence of withdrawal symptoms: irritability, depressed mood, 
restlessness, and anxiety (Hughes and Hatsukami, 1986). Most smokers find difficulties in quitting 
and the majority of successful quitters relapse. Smoking behavior is maintained mainly by ND 
(Lerman et al., 2007), and the avoidance of withdrawal symptoms (Benowitz, 2010). During 
cessation, physiological changes in the central nervous system (i.e., neurobiological adaptation) 
causes withdrawal symptoms to emerge (Hughes, 2007). The symptoms are, however, temporary 
(West and Gossop, 1994), but a relatively small proportion of smokers attempting to quit manage to 
wait until the symptoms cease, and thus relapse.
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2.2.2 Established biological pathways associated with smoking 
 
Nicotine is the primary addictive compound in tobacco smoke. Cigarette smokers can control their 
nicotine levels by altering cigarette consumption, and by controlling the number, volume and depth 
of inhalation (Hukkanen et al., 2005). Evidently, nicotine intake, the effects it initiates in the central 
nervous system, and nicotine clearance from the body are regulated by biological pathways. Only a 
few of them are well characterized, while others lack current comprehension. 
Neurobiological pathway 
Nicotine is rapidly absorbed from the small airways and alveoli of the lungs, but also through the 
mucosal layers covering the nose and mouth, and even through the skin (Armitage et al., 1978; 
Benowitz et al., 1988). From the lungs, nicotine is rushed into the pulmonary venous circulation, 
reaching the brain within 10-20 seconds (Berridge et al., 2010; Benowitz, 2010).  
In the brain, nicotine binds to nAChRs, which are ligand-activated neurotransmitter receptors, and 
consist of two major subtypes; the metabotropic muscarinic receptors and the ionotropic nicotinic 
receptors (Albuquerque et al., 2009). Both are activated by the endogenous neurotransmitter 
acetylcholine (ACh), and expressed by both neuronal and non-neuronal cells throughout the body 
(Albuquerque et al., 1995).  
The ionotropic nicotinic receptors are fast cation channels, which are sensitive to activation by 
nicotine (Albuquerque et al., 2009). Each nicotinic receptor is built up from five subunits (Dajas-
Bailador and Wonnacott, 2004). Each subunit contains a conserved extracellular NH2-terminal 
domain, four transmembrane protein domains (TM), a cytoplasmic loop of varying size and amino 
acid order, and a relatively short and variable extracellular COOH-terminal sequence (Albuquerque 
et al., 2009). The neuronal nicotinic receptors can be either homopentamers or heteropentamers. 
Figure 2 shows a simplified structure of nAChRs. To date, eight types of α-subunits (α2, α3, α4, α5, 
α6, α7, α9, and α10), and three β-subunits (from β2 to β4) have been cloned from mammalian neural 
tissues (Albuquerque et al., 2009). The α-subunits are characterized by a specific extracellular 
cysteine amino acid pair (Cys-Cys pair) near the entrance of TM1, and this Cys-Cys pair is further 
required for agonist binding (Karlin et al., 1986). 
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Figure 2. Nicotinic acetylcholine receptor (nAChR) structure. m1-m4 refer to the four 
transmembrane protein domains. (Adapted from Laviolette and van der Kooy, 2004). 
 
Some neuronal nicotinic receptors are more abundant in the mammalian nervous system than others. 
For example, the α4β2* (where * denotes the possible inclusion of additional nAChR subunits, 
complementing the number of required subunits to five) receptor is the most widely expressed 
receptor subtype in the mammalian brain, followed by expression of the sole homopentameric 
receptor α7, and α3β4* nAChRs (Dani and De Biasi, 2001). A recent study has provided an x-ray of 
the crystallographic structure of the human α4β2 nicotinic receptor (Morales-Perez et al., 2016). The 
modeled structure provides further insight into the architecture of ligand recognition, heteromer 
assembly, ion permeability and desensitization (Morales-Perez et al., 2016). Nicotinic receptors are 
mainly located in the presynaptic terminals of axons, and have a role in the modulation rather than 
processing of fast postsynaptic transmission (Vizi and Lendvai, 1999). 
The binding of nicotine at the receptor binding sites activates the release of several neurotransmitters 
in the brain (Benowitz, 2010; Dani and De Biasi, 2001; Kenny and Markou, 2001). Release of  
neurotransmitters, such as DA, serotonin, GABA, and glutamate (Dajas-Bailador and Wonnacott, 
2004; Wonnacott, 1997), induces the complex behavioral effects of smoking, including pleasure, 
arousal, reduction of anxiety and tension, enhancement of memory, increased concentration, and 
suppression of appetite (Benowitz, 1999). Figure 3 illustrates the biology of ND. DA is responsible 
for the rewarding effects of nicotine, leading to behavioral reinforcement and addiction (Nestler, 
2005; Balfour, 2004). Figure 4 shows a simplified image of neurotransmitter release by nicotine and 
the diverse psychological effects it initiates.
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Figure 3. The biology of nicotine dependence. (Adapted from Benowitz, 1999). 
 
 
Figure 4. Neurochemical and subsequent psychological effects of nicotine. (Adaptated from Benowitz, 1999). 
 
Nicotine seems to regulate signaling by modulating synaptic transmission. The process is mediated 
by the release of glutamate, which is believed to affect learning and memory by enhancing synaptic 
plasticity (Schilstrom et al., 2000). Nicotine also stimulates the release of GABA, which has been 
associated with reduced anxiety levels (Benowitz, 1999). Notably, both glutamate and GABA affect 
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DA release (Mansvelder et al., 2009). Long-term exposure to nicotine causes the desensitization of 
some receptors, which further generates upregulation. Thus, GABA-regulated inhibitory signals 
diminish, while glutamate-mediated excitatory signals persist (Mansvelder and McGehee, 2002). 
This relative deficiency of GABA over glutamate may lead to an enhanced DA release in the nucleus 
accumbens, and the mechanism may be crucial for perpetuating nicotine addiction (Mansvelder et al., 
2009).  
Nicotine increases the release of serotonin in the brain (Ribeiro et al., 1993), which is believed to be 
involved in mood regulation and aggression (Veenstra-VanderWeele et al., 2000). Low serotonin 
levels have been associated with behavioral traits, such as neuroticism and novelty seeking, which 
have been related to increased smoking behavior, increased ND, and difficulties in quitting (Lerman 
et al., 2000, Hu et al., 2000). 
Long-term chronic exposure to nicotine leads to neuroadaptation (Wang and Sun, 2005) which, 
together with receptor desensitization, leads to the development of tolerance and dependence (Dani 
and Harris, 2005). Although the role of the neurobiological pathway in smoking behavior is well-
established, the differences within it between any two smokers are less well understood. Evidence 
from electrophysiological experiments, as well as mouse studies, suggest that large differences in 
nicotine-induced behavioral effects may result from small differences in the sensitivity and 
connectivity of neurobiological pathways (Picciotto, 2003).  
 
Nicotine metabolism 
Nicotine is metabolized to several metabolites, primarily in the liver. The majority of nicotine, 
approximately 75%, is metabolized to cotinine by the CYP2A6 enzyme, a member of the cytochrome 
P450 system (Benowitz and Jacob, 1994). The rest of nicotine is metabolized to various compounds, 
such as nicotine-glucuronide, and nicotine N’-oxide, while around 10% of nicotine is excreted to 
urine unchanged (Hukkanen et al., 2005). Only 10-15% of cotinine is excreted to urine unchanged 
(Benowitz and Jacob, 1994), while the remaining is metabolized further, mainly to 3’-
hydroxycotinine (Bowman and McKennis, 1962), by CYP2A6 enzyme exclusively (Hukkanen et al., 
2005). The main path of nicotine metabolism is shown in Figure 5. 
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Figure 5. Main pathways of nicotine metabolism. (Adapted from Hukkanen et al., 2005). 
 
The amount and duration of nicotine in the body is determined by the rate of nicotine metabolism. 
The average half-life of nicotine in the blood is approximately 2 hours, which is relatively fast 
compared to the half-life of cotinine (16 hours, on average) (Hukkanen et al., 2005). The rate of 
nicotine and cotinine clearance varies considerably between individuals. On top of genetic variations, 
which will be discussed in chapter 2.3.3, several factors may explain inter-individual variability in 
metabolism. These factors include (i) physiological factors, such as diet, age, gender, circadian 
rhythm, BMI and alcohol use, (ii) pathological conditions, (iii) medications, (iv) smoking and (v) 
ethnic- or population-specific differences (Hukkanen et al., 2005; Ross et al., 2016). Variations in the 
nicotine metabolism rate have roughly been categorized into slow (<50% of activity), intermediate 
(80% of activity) and normal (100% of activity). In general, fast metabolizers smoke more and are 
less likely to quit, resulting in greater vulnerability to ND (Ray et al., 2009).
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2.2.3 Smoking quantity 
 
The number of cigarettes smoked per day (CPD) is an essential phenotype describing daily smoking 
behavior, and it can be further used as a proxy phenotype for ND, since it builds on the reported 
evidence that heavier smoking results in heavier ND and causes greater difficulties in quitting (Kaprio 
and Koskenvuo, 1988; Etter et al., 1999; Senore et al., 1998). This reflects the mechanisms which 
regulate the development of tolerance, since higher levels of nicotine intake increase the number of 
nAChR binding sites in the brain (Govind et al., 2009). However, self-reported CPD is prone to 
reporting bias, since smokers may round the amount to the nearest, or even lower, quantity of ten. In 
addition, CPD does not measure the precise depth of inhalation from the cigarette in the way 
biomarkers would. 
2.2.4 Nicotine dependence 
 
ND is the main factor in maintaining smoking behavior. Highly dependent smokers find greater 
difficulty in quitting than non-dependent smokers (Xian et al., 2007; John et al., 2004). But not all 
smokers are nicotine dependent, only about half of them meet the criteria for ND (Hughes et al., 2006; 
MacKillop et al., 2010). 
Different methods have been designed to assess ND, and the two most commonly utilized, traditional 
and global measures are the Diagnostic and Statistical Manual of Mental Disorders (DSM), 4th 
edition (DSM-IV) criteria (American Psychiatric Association (APA), 1994) and the Fagerström Test 
for Nicotine Dependence (FTND) (Heatherton et al., 1991). These measures are used both in clinics 
and research (Piper et al., 2008).  
The difficulty in designing reliable ND measures lies in the multidimensional (Piper et al., 2008) 
nature of the phenotype. Both FTND and DSM-IV are unidimensional measures. These two measures 
also approach ND from different angles: the items included in the FTND were originally designed to 
measure the concept of physical dependence (Heatherton et al., 1991), while the DSM-IV definition 
includes concepts such as cognition, behavior and psychological symptoms (APA, 1994). However, 
despite the diffrences between the two ND measures, both show similar additive genetic influences 
according to common genetic variation (Bidwell et al., 2016). 
The DSM-IV criteria are assessed by diagnostic interview and further structured into seven clusters, 
depicting loss of control regarding smoking behavior. The diagnosis of DSM-IV ND requires the 
presence of at least three out of seven criteria during a 12-month period. The DSM-IV ND criteria 
are listed in Table 1.
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Table 1. The nicotine dependence criteria in the Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition (APA, 1994). 
1 Tolerance (described as either of the following): 
a. Absence of nausea, dizziness, and other characteristic symptoms despite using substantial amounts of nicotine. 
b. Diminished effect observed with continued use of the same amount of nicotine-containing products. 
2 Withdrawal (as manifested by either of the following): 
a. The characteristic withdrawal syndrome for nicotine (refers to Criteria A and B of the criteria sets for Withdrawal from the specific substances). 
b. Nicotine (or a closely related) substance is taken to relieve or avoid withdrawal symptoms. 
3 Nicotine is often taken in larger amounts or over a longer period than was intended. 
4 A persistent desire or unsuccessful efforts to cut down or control nicotine use. 
5 A great deal of time is spent in activities necessary to obtain nicotine (e.g., driving long distances), use nicotine (e.g., chain-smoking), or to recover from its effects. 
6 Important social, occupational, or recreational activities are given up or reduced because of nicotine. 
7 Nicotine use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by nicotine. 
 
DSM-IV ND is a psychiatric measure, whereas FTND is a symptom scale assessed by a questionnaire. 
It comprises six questions, the score ranging from 0 to 10 (Fagerström, 1978). FTND may also be 
used as a dichotomous measure by applying a cut-off threshold, typically individuals scoring ≥ 4 
points being classified as nicotine dependent. The key component that best describes FTND is the 
difficulty in tolerating reduced nicotine levels (Moolchan et al., 2002). This component is depicted in 
two essential questions on the FTND questionnaire: “How soon after waking up do you smoke your 
first cigarette?” and “How many cigarettes do you smoke daily?”. Both questions have been weighted 
with high scores. The FTND questionnaire is described in Table 2.
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Table 2. Fagerström Test for Nicotine Dependence questionnaire and score. 
Questions Score 
How soon after waking up do you smoke your first cigarette? 5 minutes 3 
 6-30 minutes 2 
 31-60 minutes 1 
 after 60 minutes 0 
How many cigarettes do you smoke per day? 1-10 cigarettes 0 
 11-20 cigarettes 1 
 21-30 cigarettes 2 
 31 cigarettes or more 3 
Which cigarette would you hate most to give up? first cigarette in the morning 1 
 other 0 
Do you smoke more frequently during the first hours after 
waking up than during the rest of the day? 
yes 1 
 no 0 
Do you find it difficult to refrain from smoking in places where 
it is forbidden? 
yes 1 
 no 0 
Do you smoke even when you are so ill that you are in bed 
most of the day? 
yes 1 
 no 0 
 
In an effort to better understand the multidimensional nature underlying ND, which could be used to 
improve research and, ultimately, treatment possibilities, multidimensional measures have been 
developed, such as the Nicotine Dependence Syndrome Scale (Shiffman et al., 2004) and the 
Wisconsin Inventory of Smoking Dependence Motives (Piper et al., 2004). However, even these 
multidimensional measures have not fully succeeded in capturing ND, thus they have not been able 
to replace the unidimensional measures in research (Piper et al., 2008). 
2.2.5 Nicotine withdrawal 
 
Smoking cessation causes the appearance of nicotine withdrawal (NW) symptoms and these 
symptoms cause powerful stimuli to sustained smoking (Le Moal and Koob, 2007). Table 3 lists the 
eight DSM-IV NW criteria. Response to NW results in a cascade of events which involve, for 
example, increased expression and binding of corticotropin-releasing factor to corticotropin-releasing
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factor 1 receptors (George et al., 2007). This CRF-CRF1 receptor system has been shown to mediate 
the response to stress in rats (George et al., 2007). All in all, NW is a complex response to under-
activation of the DA system and activation of the CRF-CRF1 receptor system, since they both 
contribute to NW symptoms, which often predict relapse. The positive reinforcement induced by the 
DA system, combined with avoidance of withdrawal symptoms, establishes the basis for the 
pharmacological and physiological aspects of ND. 
 
Table 3. The nicotine withdrawal criteria in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
(APA, 1994). 
A Daily use of nicotine for at least several weeks, and 
B Abrupt cessation of nicotine use, or reduction in the amount of nicotine used, followed within 24 hours by four or more of the following signs: 
a. Restlessness 
b. Anxiety 
c. Irritability, frustration, or anger 
d. Difficulty concentrating 
e. Dysphoric or depressed mood 
f. Insomnia 
g. Decreased heart rate 
h. Increased appetite or weight gain 
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2.3 The genetics of smoking behavior and nicotine dependence 
 
Although environmental factors, such as the influence of peers and family members, as well as 
national culture and acceptance affect an individual’s smoking behavior, genetic factors also have an 
established role in the process. A substantial variety of diseases and behavioral traits, including 
substance use and abuse, aggregate within families (Bierut et al., 1998). This may be due to shared 
environmental factors, but also due to shared genetic factors. A growing body of evidence from 
family, twin and adoption studies suggests that the initiation and maintenance of substance use is 
caused by the complex interplay between the environment, individual characteristics and genetic 
vulnerability (Kaprio et al., 1984; Carmelli et al., 1992; Heath and Martin, 1993; Madden et al., 1999; 
Lessov et al., 2004; Xian et al., 2007; Petersen and Sørensen, 2011) (Figure 6).  
 
 
Figure 6. The development of dependence. 
 
While the main picture of the biology influencing ND is known (Benowitz, 2010), the molecular 
genetic architecture of nicotine addiction is scarce and poorly understood. Over the past few decades, 
smoking behavior and ND have been extensively researched, with a full spectrum of methods, from 
positional cloning and linkage-based approaches to candidate-gene and whole-genome association 
studies, having scrutinized the genome. Still, a majority of the risk variants remain to be discovered. 
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2.3.1 Heritability estimates 
 
Heritability estimates depict the percentage of phenotypic variation explained by additive genetic 
factors. Notably, the estimates are highly dependent on the sample sizes and target populations. Twin 
and adoption studies have demonstrated, via heritability estimates, that genetic factors play a major 
role in the initiation of smoking, the progression to ND, and the ability to quit smoking (Ho and 
Tyndale, 2007). ND is a highly heritable phenotype, with estimates varying from 31% to 75% (Vink 
et al., 2005; Rose et al., 2009; Lessov et al., 2004; Lessov-Schlaggar et al., 2008; True et al., 1999). 
The heritability estimates for smoking initiation are lower, varying from 35% to 55% (Li et al., 2003; 
Vink et al., 2005), and further varying between genders (Li et al., 2003). These lower estimates for 
smoking initiation emphasize the important roles of the shared and unique environments. The 
heritability estimates for NW vary between 26% and 50% (Broms et al., 2006; Xian et al., 2003; 
Pergadia et al., 2006; Pergadia et al., 2010), and the estimates are similar between adolescents and 
adults in both genders (Pergadia et al., 2010). Also, twin studies provide consistent support for the 
high heritability of nicotine metabolism (Swan et al., 2004; Swan et al., 2005; Loukola et al., 2015). 
2.3.2 Nicotinic acetylcholine receptors 
 
Since nicotine binds to nAChRs in the brain, it is likely that the genetic variation in the nAChR 
subunits have an impact on the inter-individual differences in smoking behavior. So far, members of 
the nAChR family have indeed provided the most solid genetic evidence for smoking behavior, 
although the effect sizes are small and explain merely a fraction of the proportion of phenotypic 
variance in smoking-related phenotypes. 
Several candidate gene studies and GWASs studying smoking behaviors and ND have unequivocally 
identified SNP associations within the gene cluster CHRNA5-CHRNA3-CHRNB4 on chromosome 
15q25 encoding nicotinic receptor subunits α5, α3 and β4. In detail, the 15q25 locus has been 
implicated in an increased risk of ND (Saccone et al., 2007a; Thorgeirsson et al., 2008; Saccone et 
al., 2009; Shmulewitz et al., 2016; Olfson et al., 2016) and higher smoking quantity measured with 
self-reported CPD (Thorgeirsson et al., 2008; Thorgeirsson et al., 2010; The Tobacco and Genetics 
Consortium, 2010; Liu et al., 2010; Saccone et al., 2010; Li et al., 2010; Shmulewitz et al., 2016), 
smoking initiation (Li et al., 2010), earlier onset of regular smoking (Hartz et al., 2012), and craving 
(Shmulewitz et al., 2016). In addition, the locus has been associated with an increased risk of 
downstream diseases, such as lung cancer (Amos et al., 2008; Hung et al., 2008; Saccone et al., 2010) 
and COPD (Saccone et al., 2010).  
Association signals have been reported on 15q25 with cotinine levels as well (Keskitalo et al., 2009; 
Munafo et al., 2012; Ware et al., 2016). These results have emphasized the increase in power that 
comes when using a highly informative phenotype, such as a biomarker: the alleles on 15q25 explain 
approximately 4-5% of the variance in cotinine levels (Keskitalo et al., 2009; Munafo et al., 2012; 
Ware et al., 2016), whereas the same alleles explain merely 1% of the variance in self-reported CPD 
(Thorgeirsson et al., 2008). 
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Figure 7. SNPs in high linkage disequilibrium (LD) on 15q25.1. LD pattern obtained from Finnish twin sample 
(N=2,063). Darker color refers to higher r2 value (correlation coefficient), describing the strength of pairwise LD. In 
black columns r2 is 1, meaning that two SNPs are fully correlated and provide identical information. Two rs-numbers, 
rs16969968 and rs1051730, are highlighted: they are fully correlated and perfect proxies for each other. 
 
The associated 15q25 region harbors several highly-correlated SNPs (Figure 7), and subsequent 
investigations have identified at least two distinct loci effecting smoking behavior (Saccone et al., 
2010). The most studied independent locus is tagged by a common missense variant, rs16969968 
(D398N), located in the CHRNA5 gene. This polymorphism changes a conserved amino acid from 
aspartic acid to asparagine (Bierut, 2011). The risk allele (398N) induces a more extensive receptor 
desensitization, thus decreasing calcium permeability and increasing nicotine intake (Fowler et al., 
2011). Although the allele frequencies of the SNP vary significantly between populations, studies 
have consistently produced similar effects (Li et al., 2010; Saccone et al., 2009). The many 
associations of smoking-related phenotypes have been identified using the missense variant, 
rs16969968, or another polymorphism, rs1051730 located on CHRNA3, which is fully correlated with 
the functional variant (See Figure 7). Gene-by-environment interaction has been reported, since the 
variant has been associated with an increased risk of ND among men with childhood adversity (Xie 
et al., 2012) and among early-onset smokers (age at onset ≤16 years) (Hartz et al., 2012).   
Despite the well-established role regarding smoking behavior, the CHRNA5-CHRNA3-CHRNB4 gene 
cluster has also provided inconsistent results, particularly when examined in samples of African 
American origin. As an example, in one study, a variant, rs2036527, located at the 5’ enhancer region 
of the CHRNA5 gene provided genome-wide significant evidence of association (David et al., 2012), 
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whereas, another study did not detect genome-wide significant association on the gene cluster 
(Gelernter et al., 2015).  
GWASs in general have mainly highlighted common variants contributing to smoking behavior and 
ND. However, the role of rare variation in the risk for ND in these nicotinic receptor genes has been 
less investigated. A study utilizing the sequencing approach has identified rare missense variants on 
CHRNB4, which are associated with a reduced risk of ND (Haller et al., 2012). In a recent study, 
targeted sequencing of CHRNA5 identified novel rare and low-frequency variants contributing to the 
increased risk of ND (Olfson et al., 2016). Furthermore, their results indicate that common, low-
frequency and rare CHRNA5 variants are independently associated with the risk of ND (Olfson et al., 
2016). However, the region has not been highlighted in linkage studies. 
In addition to the gene cluster on chromosome 15q25, evidence from both GWASs and candidate 
gene-based association studies has highlighted the crucial role of another gene cluster of nAChR 
subunits, CHRNB3–CHRNA6 on chromosome 8p11, in ND (Thorgeirsson et al., 2010; Bierut et al., 
2007; Saccone et al., 2007a; Rice et al., 2012). These studies have identified two distinct loci within 
the region, both located upstream or within CHRNB3 (Wen et al., 2016). Functional studies have 
suggested that the α6 subunit would have a role in nicotine-induced reward and withdrawal by 
mediating DA release (Grady et al., 2007).  
CHRNA4 has an undisputed role in mediating the responses of nicotine as a receptor subunit of the 
most abundant nAChR (α4β2) in the brain. Thus, it has been under intense investigation in smoking-
related research. Studies applying both linkage and association approaches have yielded evidence 
supporting the plausible role of CHRNA4 in smoking behavior, however, the results have been 
inconsistent. 
A meta-analysis of whole-genome linkage scans has reported genome-wide significant linkage with 
MaxCigs24 (maximum number of cigarettes smoked in a 24-hour period) on 20q13.12-q13.32 
harboring CHRNA4 (Han et al., 2010). Furthermore, a number of rare variants on CHRNA4 have been 
identified in humans through sequencing and, notably, at least some of these variants appear to be 
underrepresented among smokers (Xie et al., 2011). In fact, a rare missense variant, P451L 
(rs55915440), showed an association with a decreased risk of ND (Xie et al., 2011). On the other 
hand, a functional study has reported that rare CHRNA4 variants seem to alter the assembly of α4β2 
nAChRs, making them more sensitive to nicotine exposure (McClure-Begley et al., 2014), and one 
variant, R336C (rs56175056), also included in this functional study, has been associated with an 
increased risk of ND and with downstream smoking-related diseases, such as lung cancer and COPD 
(Thorgeirsson et al., 2016).  
Candidate gene studies have reported associations of common variants residing on CHRNA4 with ND 
phenotypes in both European Americans (Han et al., 2011; Kamens et al., 2013) and African 
Americans (Han et al., 2011). Also, a common splice site acceptor variant (rs2273500) has provided 
genome-wide significant association with an increased risk of ND, and association with reduced 
CHRNA4 expression levels in human brain and an increased risk of lung cancer (Hancock et al., 
2015), although the elevated cancer risk might be mediated by the variant’s effect on smoking.  
As the research so far has demonstrated, no single variant appears to be responsible for the effects. 
Instead, the gene harbors several susceptibility variants, both rare and common, that create 
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combinations, which affect inter-individual differences in smoking behavior, further predisposing 
one to ND.  
Although several genetic variants of different nAChR subunits have been shown to affect smoking 
behavior and ND, a large proportion still remains uncovered. The reported effects are tiny, and the 
proportion of phenotypic variance explained by the identified genetic variants is modest. The 
sequencing approach is bound to bring some additional insight on the specific roles of the subunit 
genes, and possibly enable the discovery of novel rare variants. A denser picture of the susceptibility 
variants may explain the predisposition of downstream smoking-related diseases.  
2.3.3 Nicotine metabolism 
 
Nicotine metabolism, in principal, is mediated primarily by the cytochrome P450 2A6 (CYP2A6) 
enzyme (Hukkanen et al., 2005). The gene CYP2A6 (cytochrome P450, family 2, subfamily A, 
polypeptide 6), residing on chromosome 19q13.2, is highly polymorphic, and has been linked with 
several smoking behavior phenotypes, such as CPD, ND and smoking cessation (Ray et al., 2009; 
Gold and Lerman, 2012). Individuals who carry either null or reduced activity alleles for CYP2A6 
are less dependent on nicotine (Ho and Tyndale, 2007; Gold and Lerman, 2012).  
A large-scale GWAS has identified associations between CPD and variants in CYP2A6 and CYP2B6 
(cytochrome P450, family 2, subfamily B, polypeptide 6) (Thorgeirsson et al., 2010). A ratio of two 
metabolites, 3’ hydroxycotinine:cotinine, referred to as the nicotine metabolite ratio (NMR), is an 
alternative phenotypic measure of CYP2A6 enzyme activity. In a recent GWAS meta-analysis, the 
ratio has provided genome-wide significant association with CYP2A6, CYP2B6 and CYP2A7 
(cytochrome P450, family 2, subfamily A, polypeptide 7), and notably, the results revealed three 
independent loci for CYP2A6 (Loukola et al., 2015; Baurley et al., 2016). Another recent large-scale 
GWAS meta-analysis of levels of cotinine has identified a genome-wide significant association with 
a gene variant residing in close vicinity of UGT2B10 (UDP glucuronosyltransferase 2 family, 
polypeptide B10) at 4q13.2. This gene plays a central role in nicotine metabolism by converting 
nicotine to nicotine-glucuronide (Hukkanen et al., 2005; Chen et al., 2010), and cotinine to cotinine-
glucuronide (Chen et al., 2010). The minor allele of the top SNP, rs114612145, is associated with a 
reduction in UGT2B10 function in both glucuronidation steps (Berg et al., 2010; Bloom et al., 2013). 
2.3.4 Neuronal pathways 
 
Neuregulin/ErbB signaling pathway 
As imputation reference panels have developed, and thus enabled denser mapping of the entire human 
genome, novel pathways with intriguing connections to smoking behaviors and ND have started to 
emerge from GWASs. An example of one such novel finding is the association between ND and 
ERBB4 (Erb-B2 Receptor Tyrosine Kinase 4), coding for a neuregulin receptor on 2q33 (Loukola et 
al., 2014). The same locus has yielded suggestive evidence of linkage with the regular smoker 
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phenotype (Loukola et al., 2008). Also, a recent mouse study has detected an increase in ErbB4 and 
Nrg3 (Neuregulin 3) expression during chronic exposure and withdrawal periods (Turner et al., 2014). 
Association between NRG3 and smoking cessation was also detected in a clinical trial (Turner et al., 
2014). These genes are involved in the Neuregulin/ErbB signaling pathway. Furthermore, a meta-
analysis of genome-wide linkage scans has yielded genome-wide significant evidence of linkage on 
chromosome 2q with schizophrenia (Ng et al., 2009). The precise mechanisms of this pathway in 
smoking behavior remain to be verified.  
 
Neurotrophin signaling pathway 
The neurotrophin signaling pathway is a vast and complex pathway modulating the effects of synaptic 
transmission (Bolaños and Nestler, 2004). It involves neurotrophins (Mattson and Meffert, 2006), a 
family of trophic factors, which have a role in the survival and differentiation of neural cells (Bibel 
and Barde, 2000). They regulate neurons in the nervous systems through vast signaling cascades, the 
neurotrophin signaling pathway (Reichardt 2006). Along with modulating synaptic transmission, this 
pathway also modulates the intricate processes of learning, memory, and even drug addiction 
(Bolaños and Nestler, 2004). Members of this pathway, BDNF (brain-derived neurotrophic factor) 
and NTRK2 (neurotrophic tyrosine kinase receptor 2), have previously been associated with smoking 
behavior phenotypes – smoking initiation, progression and cessation (Lang et al, 2007; The Tobacco 
and Genetics Consortium, 2010; Wang and Li, 2010). 
2.3.5 Epigenetic findings 
 
The predisposing genetic variants identified to date explain merely a fraction of the phenotypic 
variation observed in smoking behavior traits and ND, hence, the research has shifted toward 
examining the epigenetics that mediates the regulation of environmental exposures on the genome. 
Changes in DNA methylation have been associated with cigarette smoking, and it is one possible 
mechanism by which tobacco exposure predisposes one to adverse downstream health outcomes. 
Using DNA methylation data, several genes have been associated with smoking, but some have been 
more highlighted than others. As an example, CpG sites on an AHRR (Aryl-Hydrocarbon Receptor 
Repressor) have consistently been associated with cigarette smoking (Joehanes et al., 2016; Baglietto 
et al., 2017; Zhang et al., 2016). In evaluating epigenetic studies, one must consider the time- and 
tissue specificity of epigenetic marks. In the studies of behavioral traits, blood and saliva are 
frequently used sources, instead of brain tissue, due to their easier accessibility, although it is widely 
acknowledged that brain tissue would be the correct target. 
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2.4 Neuropsychiatric comorbidities  
 
Studies of genetics, neuroimaging, and nicotinic receptors support a neurobiological link between 
tobacco use and alcohol dependence, drug dependence, and several neuropsychiatric disorders, such 
as schizophrenia, depression, attention-deficit hyperactivity disorder (ADHD), and anxiety disorders 
(Williams and Ziedonis, 2004). Approximately 50–90% of individuals with mental illness or 
addiction are nicotine dependent, and the rates vary between diagnosed disorder and the study setting 
(Williams and Ziedonis, 2004). In the United States, roughly 44% of the cigarettes smoked are 
smoked by a persons with a psychiatric or substance-abuse disorder (Lasser et al., 2000). Evidence 
suggests that the rates of smoking appear to be the highest among individuals with a substance-use 
disorder or patients with a psychotic condition and slightly lower among patients with depression, 
anxiety, or personality disorder (Williams and Ziedonis, 2004).  
The possible factors that increase the risk of co-occurrence of tobacco and other drugs or 
neuropsychiatric disorders are bound to be diverse. In the first plausible scenario, biological factors 
include an increased shared genetic vulnerability, a greater susceptibility to smoking behavior and 
further progression to dependence, owing to a greater subjective experience of reward or pleasure 
mediated by the dopaminergic system. According to the second scenario, tobacco itself, or a response 
to nicotine, or both in combination, alleviate some of the symptoms related to a behavioral disorder. 
Cigarette smoking could merely be an attempt to self-medicate hallucinations or symptoms of 
depression, anxiety, boredom, loneliness, and other feelings common in this population (Williams 
and Ziedonis, 2004). 
2.4.1 Alcohol and other substance use 
 
Alcohol dependence increases the likelihood of cigarette smoking. Nicotine may act as a conditioning 
cue for alcohol use. About 60–95% of patients in addiction treatment are tobacco dependent, and 
about 40–50% are heavy smokers, defined by smoking more than 20 cigarettes per day. Such high 
rates of tobacco dependence are not merely attributable to lower socioeconomic status (Hughes et al., 
1986). 
Substance use and abuse are highly heritable, and clearly aggregate within families (Bierut et al., 
1998). The aggregation may be due to shared genetic factors, as well as shared environmental factors, 
or a combination of them. The heritability estimates increase with age, meaning that young 
individuals are more prone to their unique environments, but as they get older, genes begin to explain 
a greater portion of the phenotypic variance. This also applies to the co-occurrence of tobacco and 
alcohol use. Family and twin studies have reported that alcohol use, smoking and ND are transmitted 
within families (Dick et al., 2009; Rose et al., 2009). Studies clearly demonstrate that alcohol use and 
smoking tend to co-occur (Li et al., 2007), further suggesting a role of shared genetic predisposition. 
However, the molecular genetic mechanism underlying that shared predisposition is still largely 
unknown.
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Tobacco use in adolescents is highly correlated with other substance use, and lowers the susceptibility 
threshold for the onset of other substance abuse and psychiatric illness. Adolescents with high 
vulnerability to mental illness or other addictions have an increased risk of progressing from 
experimenting to tobacco use, and further to dependence. Adolescents with adverse family 
environments with multiple stressors are more likely to experiment with illicit drugs, such as 
marijuana, and become regular users (Gil et al., 2002). 
2.4.2 Neuropsychiatric disorders 
 
The association between smoking and schizophrenia occurs across continents despite different 
environments and rates of smoking (de Leon et al., 2002). Thus, the increased risk of smoking in 
schizophrenia may not be merely attributable to environmental or medication effects and may instead 
be due to shared genetic vulnerability of the neurobiological components mediating the rewarding 
effects. Individuals with an underlying liability of developing schizophrenia are likely to have shared 
risk factors that increase their risk of initiating smoking behavior (de Leon and Diaz, 2005).  
ADHD and tobacco smoking are among the most common and costly psychiatric and behavioral 
problems. ADHD has been estimated to occur in approximately 5–8% of children and 4–5% of adults 
(Visser et al., 2014; Kessler et al., 2006). ADHD is characterized by symptoms such as inattention, 
impulsivity, and hyperactivity (Kent et al., 2011; Sibley et al., 2012). Childhood ADHD increases the 
risk for alcohol and other drug use, abuse, and dependence (Charach et al., 2011; Lee et al., 2011). 
Also, children with ADHD are more likely to become regular cigarette smokers, initiate smoking 
earlier compared to children without the diagnosis (Kollins et al., 2005; Sibley et al., 2014), and are 
more likely to proceed as regular smokers in adolescence or adulthood (Molina et al., 2013; Sibley et 
al., 2014). The rates of co-occurrence of these two common problems are larger than expected by 
chance (McClernon and Kollins, 2008). The link between smoking and mental illness is well 
established in epidemiological studies, but its biological mechanism remains unclear, although it has 
been proposed that ADHD and smoking may involve the dysregulation of dopaminergic and 
nicotinic-acetylcholinergic circuits, and that these aberrations are partly influenced by genetic 
variations (McClernon and Kollins, 2008).  
Furthermore, evidence shows a clear connection between individual characteristics and proneness to 
smoking behavior. In particular, impulsiveness-like aspects of novelty seeking were noted as a useful 
phenotypic marker for the increased risk of substance use initiation (Bidwell et al., 2015).
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3 AIMS OF THE STUDY 
 
Family and twin studies have shown the importance of genetic factors contributing to inter-individual 
differences in the susceptibility to nicotine dependence. Recent GWASs have identified only a few 
genetic variants contributing to this genetic liability, and the majority of the genetic variants 
explaining the variance in smoking behavior are still to be discovered. This thesis aimed to identify 
and characterize the contribution of genes on smoking behavior, ND and other smoking-related co-
morbidities and traits, such as alcohol use. 
1. To replicate and extend previous linkage findings of nicotine dependence on chromosome 20, and 
to reveal possible sex-related differences underlying them.  
2. To reveal potential pleiotropic effects on 15q24-q25 by studying co-morbid smoking and alcohol 
use.  
3. To investigate the causal relationship between smoking and body mass index. 
4. To discover novel genes influencing smoking behavior in a Finnish twin family sample using 
detailed phenotype profiles.
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4 MATERIALS AND METHODS 
 
4.1 Participants 
 
4.1.1 The Older Finnish Twin Cohort (Studies I and II) 
 
The Older Finnish Twin Cohort has been established to examine the genetic, environmental, and 
psychosocial determinants affecting public health outcomes including several chronic diseases and 
health behaviors. Participants in the cohort were selected from the Central Population Registry by 
searching for twin pairs (i.e., individuals born on the same day) with the same last name at birth, of 
the same sex, and born in the same local municipality. The cohort included same-sex MZ and DZ 
twin pairs born in Finland before 1958, with both members still alive in 1975 (Kaprio and Koskenvuo, 
2002). Questionnaires were distributed in 1975, 1981, and 1990. The 1981 questionnaire was 
delivered to all twins who were still alive, whereas in 1990, the questionnaire was restricted to pairs 
born between 1930-1957, with both co-twins resident in Finland in 1987, if they had replied to at 
least one of the previous surveys. The cohort was expanded in 1996 and 1997 to include opposite-sex 
twin pairs born in 1938-1949. Like same-sex twin pairs, the opposite-sex twin pairs were identified 
from the Central Population Registry. The entire Older Finnish Twin Cohort comprises 15,388 twin 
pairs. 
Based on the health questionnaires conducted in 1975, 1981, 1990, and 1996-1997, twin pairs 
concordant for cigarette smoking were selected from the Older Finnish Twin Cohort and recruited 
along with their family members to form a Family Study on Nicotine Dependence (NAG-FIN) sample. 
The sample was established to examine genetic and environmental factors contributing particularly 
to smoking behavior and ND. Data collection, taking place in 2001-2005, included a computer-
assisted telephone diagnostic interview based on an adaptation of the Semi-Structured Assessment 
for the Genetics of Alcoholism (Bucholz et al., 1994) and the Composite International Diagnostic 
Interview (Cottler et al., 1991), a blood sample for DNA extraction and a mailed self-report 
questionnaire. The tobacco section for the diagnostic interview was derived from the CIDI (Cottler 
et al., 1991), and included FTND (Heatherton et al., 1991) and DSM-IV (APA, 1994) assessment of 
ND. In addition, participants were asked about their lifetime smoking behavior, from smoking 
initiation to attempted cessation, from the quantity of use for current smokers or the most recent 
heaviest period of use to DSM-IV symptoms of NW. Thus, the sample consists of unique, detailed 
phenotypic profiles which aim to portray the complex landscape of smoking behavior. Data from this 
sample were used in Studies I (N=1,302) and II (N=1,715).  
4.1.2 The National FINRISK Study (Studies III and IV) 
 
The National FINRISK Studies have monitored risk factors in major chronic and non-communicable 
diseases from 1972 to 2012, in 5-year intervals (Borodulin et al, 2015). For each survey, an 
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independent, random, and representative sample from four to six different parts of Finland, depending 
on the year of survey, was drawn from the national population register. In the early stages of the 
survey, in 1972 and 1977, data collection was restricted to North Karelia and Northern Savo as part 
of the North Karelia Project (Borodulin et al, 2015). In subsequent years of the survey, new areas  
were added to improve the representativeness of the survey (Borodulin et al, 2015); Turku and the 
Loimaa region in southwestern Finland in 1982, the capital area including two major cities, Helsinki 
and Vantaa, in 1992, and provinces of Northern Ostrobothnia and Kainuu in northwestern Finland in 
1997. In addition, Lapland was included in the surveys in 2002 and 2007. The surveys included a 
self-administered questionnaire, with self-reported information about health-related habits, including 
tobacco and alcohol use, physical measurements and blood samples. Data from cohorts 1992, 1997, 
2002, and 2007, including 26,800 genotyped participants (53% women) with a mean age of 48 years, 
were used in Studies III and IV. In 2007, no blood samples were collected in Lapland, restricting the 
participation of Lapland samples merely to year 2002. Table 4 describes the distribution and 
demographics of the National FINRISK Study. 
 
Table 4. The distribution and demographics of the National FINRISK Study participants by year of the 
survey. 
 
 
 
 
 
Regions: A = North Karelia, B = Northern Savo, C = Turku and the Loimaa region in southwestern 
Finland, D = The capital area including two major cities, Helsinki and Vantaa, E = Provinces of Northern 
Ostrobothnia and Kainuu in northwestern Finland, and F = Lapland. 
 
4.1.3 The Health 2000 Survey (Study III) 
 
The study was aimed to provide an up-to-date comprehensive picture of health and functional ability 
in the working-aged and aged population in Finland. For the main survey, a random and nationally 
representative sample was drawn of the population aged 30 and over in order to investigate general 
health, major chronic conditions, determinants of health and disease, among other things. The survey 
was carried out in 2000-2001, and included interviews, self-administered questionnaires, physical 
measurements, determinations from blood samples and clinical examinations (Heistaro, 2008). Data 
of 5,792 genotyped participants (55% women), with a mean age of 54 years, were used in Study III. 
The data included self-reported information on tobacco and alcohol use. 
Year of 
Survey 
Region Total 
A B C D E F 
1992 1,316 1,513 1,447 1,284 0 0 5,560 
1997 1,577 1,320 1,178 1,558 1,248 0 6,881 
2002 1,623 1,190 1,227 1,427 1,244 1,644 8,355 
2007 1,225 1,234 1,183 1,126 1,236 0 6,004 
Total 5,741 5,257 5,035 5,395 3,728 1,644 26,800 
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Replication samples 
Additional individual replication samples were included in Studies II and III. These samples are 
described in more detail in the original papers. Table 5 summarizes the replication samples and their 
references. 
 
Table 5. Replication samples. 
Sample Abbreviation N Study Reference 
FinnTwin12  581 II Kaprio 2006; Kaprio 2013 
Australian twin family sample NAG-OZALC 5,743 III Heath et al., 2011 
Young Finns Study YFS 1,982 III Raitakari et al., 2008 
 
 
4.2 Phenotypes 
 
4.2.1 Smoking quantity (Studies I, II, III and IV) 
 
Smoking quantity was examined throughout the studies. In the NAG-FIN sample, the question of 
smoking quantity was addressed to participants who reported regular smoking (i.e., had smoked at 
least 100 cigarettes in their lifetime and at least once a week for at least two consecutive months). In 
the data, smoking quantity was defined as CPD and MaxCigs24. Originally, CPD was determined by 
the number of cigarettes smoked per day during the period of the heaviest smoking as a categorical 
measure comprising eight categories: 1-2, 3-5, 6-10, 11-15, 16-19, 20-25, 26-39, ≥40. Later, the 
variable was modified for quantitative use by taking class means from each category. CPD was 
analyzed as a continuous variable in Study II, whereas MaxCigs24 was examined in Studies I and II.   
Study III focused on scrutinizing smoking quantity on a larger scale using two population-based 
samples, the National FINRISK Study and the Health 2000 Survey. In both samples, smoking 
quantity was derived from quantitative self-reported CPD. Equally, in both samples, the participants 
were asked, how many cigarettes, or equivalent tobacco products, they smoke daily or used to smoke 
before quitting. The answers from different tobacco products were summed as a single quantitative 
measure to be analyzed as a quantitative trait. CPD measures from the two different population 
samples were merged to be one large dataset. Additionally, the summed quantitative measure of CPD 
was analyzed as a binary variable with light smoking controls and heavy smoking cases. Table 6 
shows the descriptive statistics of smoking quantity in Study III.
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Table 6. Descriptive statistics of the smoking quantity variables utilized in Study III.  
Smoking quantity in a Finnish population-based sample 
 % Males Mean SD Range 
Quantitative CPD, N=8,356 56 14.8 8.9 1-100 
Heavy smokers (CPD>20), N=1,076 83 31.1 7.6 21-100 
Light smokers (CPD≤10), N=3,624 40 6.9 3.1 1-10 
CPD, cigarettes per day; SD, standard devision. 
 
4.2.2 Nicotine dependence (Studies I and II) 
 
In the NAG-FIN sample, ND has been determined with DSM-IV ND (APA, 1994) and FTND 
symptoms (Heatherton et al. 1991). They both measure ND, but with slightly differing aspects, and 
thus correlate only moderately (Broms et al, 2007; Hughes et al, 2004). In this thesis, we utilized 
these two ND measures. In Studies I and II, we examined DSM-IV ND as a binary diagnosis, 
requiring three symptoms or more out of seven to occur at the same time within a 12-month period. 
In addition, in Study II, the DSM-IV ND was analyzed as a continuous variable with the number of 
DSM-IV symptoms of ND ranging from 0 to 7. FTND was used in Study I as a continuous measure 
of scored points from the questionnaire, with a score ranging from 0 to 10, and as a binary trait with 
a cut-off of 4 points. In general, an individual scoring four points or more from the FTND 
questionnaire is considered to be a nicotine dependent smoker (Heatherton et al., 1991). 
4.2.3 Nicotine withdrawal (Study II) 
 
Regular smokers (see description in paragraph 4.2.1) in the NAG-FIN sample were asked about 
symptoms they might have had in the first 24 hours after they stopped or cut down on cigarettes. They 
were queried about each DSM-IV NW symptom (described in Table 3). Individuals were diagnosed 
with DSM-IV NW if they met the criteria of endorsement of at least four out of eight symptoms 
within 24 hours of quitting or reducing the use of cigarettes (APA, 1994). 
4.2.4 Alcohol use (Study III) 
 
Alcohol use was examined in Study III. In the National FINRISK Study, the self-reported measure 
of weekly alcohol consumption, defined as grams (g) per week, was derived from the question: “How 
many glasses (restaurant measures) or bottles of alcohol beverages did you drink during the last 
week?”. In the Health 2000 Survey, on the other hand, the participants were asked: “How often and 
how much did you drink alcohol beverages during the past 12 months?”. One drink (a 330-ml bottle 
of beer, a 12-cl glass of wine or a 4-cl portion of spirits) was estimated to include 12 g of pure alcohol. 
In both sample sets, an average consumption of alcohol per week (g/week) was calculated for each 
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individual based on the knowledge of how many grams of ethanol the consumed alcohol beverages 
contain. In the National FINRISK Study, the week’s drinks were summed in the g/week variable. In 
the Health 2000 Survey, alcohol drinks consumed during the past 12 months were summed and 
divided as an average alcohol use per week (g/week).  
After excluding the possibility of sample stratification by first modeling independent samples and 
adjusting for study region (i.e., ensuring that the sample does not include subpopulations that would 
vary statistically from the overall population), the samples were merged in order to form a single 
large sample. Thus, the data included 31,812 individuals with information on alcohol use. The trait 
was analyzed as a quantitative, categorical, and binary trait. In the quantitative approach, g/week were 
logarithmically transformed, which provided the best fit for the sample. A total of 20,298 individuals 
were included in the analysis. Table 7 illustrates the descriptive statistics of alcohol use variables in 
Study III. For categorical and binary analyses, alcohol consumption was analyzed as standard drinks 
per week, one alcohol drink containing 12 grams of pure ethanol. For the categorical alcohol trait, 
individuals were categorized as abstainers and low-frequency drinkers (less than 1 drink per week), 
light drinkers (1-2 drinks per week), moderate drinkers (3-7 drinks per week for women, and 3-14 
drinks per week for men), and heavy drinkers (over 7 drinks per week for women, and over 14 drinks 
per week for men). In the binary analyses, alcohol use was dichotomized into those drinking at least 
one drink per week (drinkers) versus those abstaining or drinking less than one drink per week (i.e., 
less than 12 g of alcohol per week) (abstainers and low-frequency drinkers). This low cut-off for 
drinking ensures that the sample has the power to detect associations. Also, as heavier alcohol use is 
frequently associated with smoking, the lower cut-off for drinking can assist in detecting an 
association which is not veiled by dual use of the two substances. In addition, evidence suggests that 
even one drink per week increases the likelihood of mortality, while two to six drinks per week 
increase mortality by 40% (Pyryla et al., 2016). 
 
Table 7. Descriptive statistics of quantitative alcohol use analyzed in Study III. 
Alcohol use (g/week) in a Finnish population-based sample 
N % Males Mean SD Range 
20,298 53 97.6 124.6 4-2219 
g, grams; SD, standard deviation. 
 
4.2.5 Body mass index (BMI) (Study IV) 
 
In Study IV, causal inference was assessed between self-reported smoking status and BMI. 
Participants were stratified into current, former and never cigarette smokers, and further stratified by 
sex. The variables height (m) and weight (kg) were directly measured, and BMI was calculated as 
weight/height2. 
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4.2.6 Confounders 
 
If a factor is statistically related to both the outcome and the exposure, it is a confounding variable. 
Such confounding can be controlled by adjusting the statistical model for that variable. The 
confounding factor may be commonly accepted as causing confounding for the exposure in question, 
and it should be accounted for in the analyses. Alternatively, its role might be uncertain, and it should 
be investigated if a potential confounding variable changes the statistical significance for the observed 
risk estimates each time in any study sample before conducting the final statistical model.  
For smoking behavior and ND, sex and age are commonly accepted confounding factors, and thus 
they were included in the statistical models throughout the studies (Studies I-IV). In addition, Study 
III examined smoking and alcohol use, which are highly co-morbid traits. Hence, the role of 
confounding between them was tested. Smoking proved to be a significant confounding factor for 
alcohol use, and vice versa. Therefore, the analyses of alcohol use as an exposure were adjusted for 
age, sex and quantitative CPD, whereas the analyses of smoking quantity as an exposure were 
adjusted for age, sex and alcohol use (g/week; logarithmically transformed). 
In Study II, population stratification and relatedness within the sample were accounted for by the 
covariance matrix. This was determined by calculating a relatedness matrix from the genome-wide 
genotype data, ultimately representing genetic similarity across individuals. 
 
 
4.3 Genotyping, imputation and quality control 
 
4.3.1 Microsatellite markers (Study I) 
 
DNA samples from the NAG-FIN data were first genotyped in 2005 in a genome-wide scan which 
included 380 microsatellite markers (363 autosomal markers), 11 of which were located on 
chromosome 20 between 2.90 and 100.63 centimorgans (cM) (a distance along a chromosome), 
yielding an average distance of 9 cM between the markers. Two different platforms, ABI (Applied 
Biosystems, Foster City, CA, USA) and MegaBASE (Amersham Biosciences, Piscataway, NJ, USA) 
were used. Samples were genotyped at the former Finnish Genome Center, currently known as the 
Genotyping Unit of the Technology Center at the Institute for Molecular Medicine Finland (FIMM). 
The genetic location of each marker was defined using the published deCODE genetic map locations 
(Kong et al., 2002). For markers that were not included in the deCODE genetic map, linear 
interpolation was used for obtaining estimates of the genetic locations of these markers by using the 
physical and the genetic locations of the immediately flanking deCODE markers (Loukola et al., 
2008).  Figure 8 shows the position of the markers on chromosome 20.
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Figure 8. Microsatellite markers and their positions on 
chromosome 20. Markers with gray highlight are the ones that 
were genotyped in the earlier genome-wide scan, white markers 
highlight fine-mapped regions. 
 
Based on an earlier whole-genome scan showing the strongest evidence of linkage between 
MaxCigs24 and chromosome 20 in the NAG-FIN sample (Saccone et al., 2007b), the top four markers 
were selected and genotyped in an additional sample (N=759 participants from 206 families) in 2009. 
In addition to these four markers, 14 additional markers were genotyped for fine-mapping purposes 
in both the original whole-genome scan sample and the additional sample. The genotyping was 
performed using the ABI (Applied Biosystems) platform, and the genotyping was done at the Finnish 
Genome Center. After fine-mapping, chromosome 20 harbored 25 microsatellite markers in total, 
with an average distance between markers of 4 cM. Within the fine-mapped region including the 18 
markers, the average distance between markers was 2.4 cM.  
A genotyping success rate was calculated for each sample and marker, after which Mendelian 
inconsistencies were checked with the programme PedCheck (O’Connel and Weeks, 1998), which 
resulted in the removal of eight families yielding more than three Mendelian inconsistencies. No 
further errors in pedigrees were detected. For locating the unlikely but Mendelian consistent 
genotypes, we utilized the programme MERLIN (Abecasis et al., 2002), which identifies the unlikely
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genotypes by an error-detection algorithm and erases them from the data with the command Pedwipe. 
A genotyping success rate threshold of > 85% was applied to the final data. 
Study I was performed in two phases using two data sets: replication data (Study I A) and combined 
data (Study I B) (reported as Study 1 and Study 2, respectively, in the original publication). In the 
analyses, data for Study I A consisted of 759 participants (genotyped in 2009) with 18 genotyped 
markers (4 whole-genome scan markers and 14 fine-mapping markers) on chromosome 20. For Study 
I B, two data sets, the existing whole-genome linkage scan (genotyped in 2005) with 508 participants 
(Loukola et a., 2008; Saccone et al., 2007b), and the data included in Study I A (759 participants) 
were merged. Thus, Study I B consisted of 1,302 participants, of whom (a) 485 were genotyped with 
all 25 markers (11 genome-scan markers and 14 additional markers for fine-mapping), (b) 794 were 
genotyped with 18 markers (4 genome-scan markers and 14 fine-mapping markers), and (c) 23 were 
genotyped with only 11 genotyped genome-scan markers (i.e., sample was included in the whole-
genome linkage scan, but the fine-mapping was unsuccessful). 
4.3.2 Single nucleotide polymorphisms (Study II-IV) 
 
Genome-wide genotyping for the NAG-FIN sample was performed using two high-density SNP 
arrays, the Human670-QuadCustom Illumina BeadChip (Illumina, Inc., San Diego, CA, USA) 
(N=1,162) and the Illumina Human Core Exome BeadChip (N=901), at the Welcome Trust Sanger 
Institute and at the Broad Institute of MIT and Harvard. In the pre-imputation quality control protocol, 
SNPs with a MAF < 1%, a SNP and sample call rate < 95% (< 99% for SNPs with MAF < 5%), and 
a Hardy–Weinberg equilibrium (HWE) test P < 1x10-6 were excluded from the data generated with 
the Human670-QuadCustom Illumina BeadChip. Similarly, SNPs with a minor allele count < 2, 
sample call rate < 98%, SNP call rate < 95% (< 99% for SNPs with MAF < 5%), and HWE test P < 
1x10-6 were excluded from the data generated with the Illumina Human Core Exome BeadChip. 
Samples were also excluded if they contained non-Finnish ancestry, excess heterozygosity, duplicates 
or were of ambiguous sex. Pre-phasing of the data was performed with SHAPEIT2 (Delaneau et al. 
2013).   
The data was imputed with IMPUTE version 2.3.1 (Marchini et al., 2007; Howie et al., 2009; Howie 
et al., 2012) utilizing a combined reference panel consisting of the 1000 Genomes September 2013 
release and an all-Finnish low-pass whole genome sequence (N=1,941) from the SISu project, both 
of which have been conducted using the human reference sequence GRCh37/hg19 assembly. 
Imputation was followed by post-imputation exclusion criteria, which were applied for each SNP. 
The criteria included an effect allele frequency < 1% and > 99%, a SNP call rate < 95%, HWE P < 
1x10-6, and imputation info < 0.8. Both quality controls and imputation for the GWAS data were done 
at FIMM, University of Helsinki, Helsinki, Finland. 
For Study III, three SNPs were selected for genotyping based on a previous meta-analysis of binary 
CPD contrasting heavy smoking cases vs. light smoking controls (Saccone et al., 2010) in both the 
National FINRISK Study and the Health 2000 Survey samples, at the same time. The SNPs included 
rs16969968 (CHRNA5; locus 1), rs578776 (CHRNA3; locus 2), and rs588765 (CHRNA5; locus 3). 
DNA was derived from whole blood samples, from which the DNA was extracted at the laboratory 
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of molecular genetics at the National Institute of Health and Welfare (previously called the National 
Public Health Institute). Genotyping of the DNA samples was carried out using standard protocols of 
iPLEX Gold technology on the MassARRAY System (Sequenom, San Diego, CA, USA). For all 
SNPs, the success rate was > 99%, and they were in HWE (P > 0.05). MAFs were 32%, 32%, and 
38% for rs16969968, rs578776, and rs588765, respectively.  
4.4 Statistical methods 
 
4.4.1 Linkage analysis (Study I) 
 
Linkage analysis was performed in Study I using selected smoking behavior traits and microsatellite 
markers on chromosome 20. Both single- and multipoint linkage analyses were performed using 
MERLIN (Abecasis et al., 2002). In singlepoint analysis, linkage was calculated for each marker 
separately, while multipoint analysis took into account the adjacent markers as well. The binary 
DSM-IV diagnosis for ND and FTND were analyzed using the nonparametric linkage analysis by 
Whittmore and Halpern’s NPL statistics (Whittmore and Halpern, 1994), which tests for allele sharing 
among affected individuals. The analysis was performed using two types of allele sharing statistics: 
pairs and all. The pairs option counts the number of identity-by-descent (IBD) (referring to segments 
of DNA shared by individuals that has been inherited from a common ancestor without any 
intervening recombination events) shared alleles for each pair of affected relatives, whereas the all 
option creates arbitrary groups of individuals to count the IBD alleles shared by all. Continuous traits, 
FTND and MaxCigs24, were analyzed with variance components linkage analysis using MERLIN 
(Abecasis et al., 2002).  
In cases where significant linkage was observed, the signal was followed up by sex-stratified 
analyses. Additionally, in Study I B, regular smokers were divided into groups of current and former 
smokers, and analyzed separately. The results of linkage analysis are presented as LOD scores, and 
for any trait reaching statistically significant linkage, the maximum LOD (MLOD) score, showing 
the most significant results of the trait, is presented. 
Simulation studies provide a means to determine the empirical significance for detected linkage 
findings. In Study I, simulations were performed using MERLIN (Abecasis et al., 2002), which 
simulated 1,000 genome-wide linkage scans of comparable structure, and analyzed each simulated 
scan identically to the original data analysis. In MERLIN, simulation is created by a gene-dropping 
pattern. While maintaining the genetic map, phenotype data, pedigree structure, and missing genotype 
data patterns, it creates comparable data with random marker genotypes. The data are simulated under 
the hypothesis of no linkage, and thus, any detected linkage is due to chance alone. This allows for 
the evaluation of the false-positive rate of the data set. The empirical p-value for a certain LOD score 
was defined as the proportion of simulated genomes where the LOD score in question was reached 
or exceeded.
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4.4.2 Association analyses (Study II-IV) 
 
GWAS 
In Study II, we performed a GWAS with selected smoking behavior phenotypes. The analysis was 
performed using GEMMA (Genome-wide Efficient Mixed Model Association) (Zhou and Stephens, 
2012). Allelic dosage data were used to model the genotypes. The genetic associations were acquired 
with a linear mixed model in which the phenotypeS of interest (smoking quantity defined as CPD and 
MaxCigs24), DSM-IV NW (diagnosis and symptoms), and DSM-IV ND (diagnosis and symptoms) 
were the dependent variables and the coded allele dose (posterior mean genotypes) the independent 
variable. The obtained effect sizes of the binary traits, DSM-IV NW diagnosis and DSM-IV ND 
diagnosis, were transformed to the odds-scale for more meaningful interpretation using the formula 
suggested by Pirinen and colleagues (2013). The transformation has been shown to provide accurate 
effect sizes when the data fulfills the following criteria: the genetic effects are small, the case-control 
ratio is balanced and the MAF is above 5% (Pirinen et al., 2013). P-values below 5x10-8 were 
considered to be genome-wide significant. 
In Study II, genomic loci showing genome-wide significant association were further targeted with 
conditional analyses to determine whether the signal represents an independent effect, or whether 
there is more than one signal affecting the smoking behavior. Thus, we performed additional 
association analyses for loci of interest, adjusting the analysis for the SNP with the lowest p-value. 
The next strongest signal was identified from the results and included in the subsequent round of 
conditional analyses in an iterative fashion until no residual genome-wide significant signal (P < 
5x10-8) remained. 
 
Candidate gene analysis 
In Study III, associations were tested between three SNPs of interest, rs16969968 (locus 1), rs578776 
(locus 2), and rs588765 (locus 3), and smoking quantity, using both quantitative self-reported CPD 
and dichotomous CPD (light versus heavy smokers). For quantitative CPD, the associations were 
modeled using negative binomial regression, which provided the best fit for the trait distribution in 
the large, merged population-based sample. Associations between the loci and dichotomous CPD 
were evaluated using logistic regression. Each SNP was tested separately in a single-SNP model. In 
addition, to test whether additional loci contribute to dichotomous smoking quantity over and above 
the effect of locus 1, joint models for locus 1 and each of the other two loci were analyzed. Throughout 
the analyses, genotypes for all three SNPs were coded additively, as the number of copies of the minor 
allele.   
Alcohol use was examined as either a quantitative, categorical, or dichotomous trait. Associations 
between log-transformed alcohol use (g/week) and the SNPs were modeled using linear regression, 
4-level categorical alcohol use (abstainers and low-frequency drinkers, light, moderate, and heavy 
drinkers) was tested using multinomial logistic regression, and logistic regression was performed for 
dichotomous alcohol use (abstainers and low-frequency drinkers versus drinkers). 
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A goodness-of-fit test was used in order to capture the best fit for the locus-specific dominance model 
(recessive, dominant, additive, and co-dominant). The additive model provided the best fit for the 
traits and loci, with the exception of dichotomous alcohol use and locus 3, for which the co-dominant 
model was most suitable. 
Acknowledging the fact that large population-based cohorts might include former alcoholics as 
participants, and that they might end up in the abstainers group when categorizing the group of 
abstainers and low-frequency drinkers, the analysis of dichotomous alcohol use was repeated among 
never smokers. This model inhibits the confounding effect of smoking.  
All statistical analyses in Study III were performed with Stata 11.1 (StataCorp. Stata Statistical 
Software: Release 11. College Station, TX: StataCorp LP, 2009).  
4.4.3 Mendelian randomization meta-analysis (Study IV) 
 
In Study IV, the National FINRISK Study sample was included in a large-scale meta-analysis 
conducted by the Causal Analysis Research in Tobacco and Alcohol (CARTA) consortium 
(http://www.bris.ac.uk/expsych/research/brain/targ/research/collaborations/carta/). The meta-
analysis was performed using data on individuals (≥ 16 years) of European ancestry from a total of 
29 studies. For each cohort, on-site Mendelian Randomization analyses between a SNP, rs16969968 
(CHRNA5), and BMI were performed using linear regression, stratified by smoking status and sex. 
Hence, placed into the model of Mendelian Randomization (see chapter 2.1.2), rs16969968 refers to 
factor Z, which has a robust effect on smoking (X), but does not influence BMI (Y). BMI was 
analyzed as a log-transformed variable assuming an additive genetic model. Hence, each effect size 
could be exponentiated to represent the percentage increase in BMI per minor (risk) allele. Analyses 
were conducted using Stata 13 (StataCorp. Stata Statistical Software: Release 13 College Station, TX: 
StataCorp LP, 2013). 
The results from individual studies were pooled for fixed effects meta-analyses using the “metan” 
command in Stata (version 13). The “metareg” command was used to examine whether SNP effects 
varied by sex. Since no evidence for effect modification by sex was observed, the estimates of effect 
sizes from different data sets were pooled together.  
4.4.4 Infering the functional potential of the SNPs (Study II) 
 
In Study II, the functional potential of the genome-wide significant SNPs was assessed utilizing the 
publicly available database Ensembl Variant Effect Predictor (McLaren et al., 2016). To examine 
whether the SNPs have an effect on expression levels of nearby genes, eQTL analyses were performed 
using blood- and brain tissue-derived data from the Genotype-Tissue Expression (GTEx) database 
(GTEx Consortium, 2015) and brain tissue-derived data from the Brain eQTL Almanac 
(BRAINEAC) database (Ramasamy et al., 2014). To assess whether the SNPs affect the methylation 
within adjacent genes, blood-derived meQTL data from the mQTLdb (mqtldb.org) (Gaunt et al.,
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2016) and BIOSqtl (genenetwork.nl/biosqtlbrowser) (Bonder et al., 2016) databases was examined, 
as well as meQTL data derived from fetal brain (epigenetics.essex.ac.uk/mQTL) (Hannon et al., 
2016).
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5 RESULTS AND DISCUSSION 
 
5.1 Genetics of nicotine dependence 
 
5.1.1. Chromosome 20 shows evidence of linkage with ND 
 
Chromosome 20 is a highly relevant candidate chromosome for genetic mapping studies for smoking-
related phenotypes, since it harbors the nAChR subunit α4 at 20q13.2–13.33. The α4β2 receptor is 
the most widely expressed receptor subtype in the mammalian brain (Dani and De Biasi, 2001), and 
thus plays a major role in mediating and modulating the release of various neurotransmitters 
(Benowitz, 2010). Previous studies utilizing a subset of 505 individuals from the NAG-FIN sample 
have yielded linkage on 20p13 with DSM-IV ND (Loukola et al., 2008) and on 20q13 with 
MaxCigs24 (Saccone et al., 2007b; Han et al., 2010). Thus, in Study I, chromosome 20 was 
specifically targeted with linkage analyses using the NAG-FIN sample, in order to replicate and 
extend previous findings of ND. The analyses were performed in two phases, using a replication 
sample (Study I A), and a combined sample (Study I B). 
 
Table 8. Linkage results from single- and multipoint linkage analyses in Study I A and I B. 
Chromosome 20 linkage results for DSM-IV ND diagnosis 
 
Study I A (N=759) Study I B (N=1,302) 
Singlepoint 
LOD Multipoint LOD 
Singlepoint 
LOD Multipoint LOD 
Marker cM Location Pairs Pairs Pairs Pairs 
D20S85
2
39.56 20p12.1 1.122 1.937 0.403 0.793 
D20S11
2
44.35 20p12.1 2.101 2.138 1.743 1.074 
D20S43
2
48.54 20p11.23 0.89 2.767 0.894 1.483 
D20S91
2
50.95 20p11.23 1.581 3.412 1.462 2.348 
D20S87
1
53.34 20p11.21 3.806 3.221 1.675 1.819 
D20S19
5
56.35 20q11.21 1.297 2.894 1.332 1.65 
D20S88
4
58.40 20q11.23 1.83 2.363 1.442 1.182 
D20S10
7
61.78 20q12 1.133 1.761 0.978 0.824 
D20S89
9
66.42 20q13.11 1.924 1.005 1.071 0.383 
Bolded values refer to statistifically significant LOD scores. 
 
In Study I A, a sample of 759 individuals yielded significant linkage with the DSM-IV ND diagnosis 
on 20p11.21 (D20S871, MLOD score 3.8 (singlepoint)) (Table 8). Only pairs-results are presented in 
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the table, since pairs and all statistics provided similar results. This region harbors several genes, such 
as NXT1 (NTF2-like export factor 1), GZF1 (GDNF-inducible zinc finger protein 1), NAPB (N-
ethylmaleimide-sensitive factor attachment protein, beta), and a cystatin locus, which contains the 
majority of the type-2 cystatin genes and pseudogenes. These type-2 cystatin proteins are a class of 
cysteine proteinase inhibitors found in a variety of human fluids and secretions. The cystatin locus 
within this region is of interest, since cystatins have been shown to resemble the α subunits of nAChRs 
(Steinlein et al., 1996). Both cystatins and α subunits contain four cysteine residues, which form two 
disulfide bonds serving as agonist binding sites in nAChRs (Steinlein et al., 1996). Other genes within 
the linkage locus do not provide as clear a connection as the cystatins.   
Increasing the sample size from 759 to 1,302 in Study I B shifted the linkage peak from 20p11.21 
(53.34 cM) to 20p11.23 (50.95 cM), showing linkage with DSM-IV ND diagnosis (D20S912, MLOD 
score 2.3 (multipoint)) (Table 8). In the previous genome-wide linkage scan utilizing a subset of 505 
individuals from the NAG-FIN sample (Loukola et al., 2008), linkage was observed at 20p13. 
Evidently, an increase in sample size has shifted the linkage region from the distal part of the short 
arm toward the centromere. In our study, linkage was observed at 20p12.1 (D20S112, MLOD score 
1.7 (singlepoint)). This marker is located in an intron of PCSK2 (proprotein convertase 
subtilisin/kexin type 2); the gene has three transcript variants, and the numerical order of the intron is 
related to the transcript variant. PCSK2 serves as a catalyst, releasing protein hormones and 
neuropeptides from their precursors. PCSK2 is predominantly expressed in thyroid, and only at 
moderate levels in other organs and tissues, including the human brain (genome.ucsc.edu). 
Interestingly, PCSK2, along with other adjacent genes within that region, has been reported to 
associate with smoking cessation in a GWAS (Uhl et al., 2010). Stratification by smoking status did 
not yield any significant linkage signals. 
No evidence of linkage was observed with the binary FTND trait, and the continuous FTND yielded 
merely moderate linkage at 20p12.1 (D20S112, MLOD score 1.5 (singlepoint); data not shown). 
However, both binary DSM-IV ND diagnosis and continuous FTND highlight the same marker 
(D20S112) in singlepoint analyses. Further scrutiny showed significant correlation between the two 
ND measures, with a tetrachoric correlation of 0.69 (P < 0.001, standard error (SE) 0.03). Although 
the two ND measures demonstrate a similar direction in the results, it has been proposed that they 
measure ND from slightly different points of view (Hughes et al., 2004, Broms et al., 2007). Still, the 
results could have been improved using a measure of shared variance across the two traits (Bidwell 
et al., 2016), which, however, was not tested in Study I. Clinical trials support the distinction between 
the two measures, as DSM-IV ND and FTND rarely yield consistent results in them (Moolchan et al., 
2002; Piper et al., 2006; DiFranza et al., 2010).  
MaxCigs24 did not yield significant linkage on chromosome 20 (D20S119, MLOD score 1.3 
(singlepoint); data not shown). Thus, the linkage detected in Study I B is modest compared with the 
two previous studies reporting linkage on chromosome 20 with MaxCigs24 (Saccone et al., 2007b; 
Han et al., 2010). Both previous reports included a subset of the sample used in Study I B.  
Whenever significant linkage was observed in Study I B, regular smokers were divided into groups 
of current and former smokers, and analyzed separately, which did not provide any evidence of 
linkage. 
Results and discussion 
 
62 
   
 
5.1.2 Linkage results reveal sex differences 
 
Men and women differ in their smoking behaviors. Women are less likely to attempt quitting and 
may be more vulnerable to relapse compared to men (Becker and Hu, 2008). However, it is unclear 
which factors influence the difference. Women tend to respond more to environmental smoking cues 
than men, which may be influenced by the hormonal changes during the menstrual cycle (Lynch, 
2009). Clear pharmacological sex differences in smoking and ND suggest that genetic factors may 
play a role in the sex differences of ND (Benowitz and Hatsukami 1998).  
To address the importance of identifying genetic factors that explain sex differences in ND, sex-
stratified linkage analyses for DSM-IV ND were performed on chromosome 20 (Study I). A better 
understanding of the factors that influence the neurobiology underlying sex differences in smoking 
behavior, including genetic factors, will aid in designing individualized and optimized smoking 
cessation therapies, and further lead the way to sophisticated precision medicine.  
In the replication sample of Study I A, a clear distinction between linkage loci was observed. Males 
(N=374) provided suggestive evidence for linkage at 20p11.21 (D20S871, MLOD score 2.6 
(singlepoint)), whereas females (N=385) yielded significant linkage at 20q11.23 (D20S884, MLOD 
3.4 (singlepoint)). Table 9 shows the most significant linkage results from the sex-stratified analyses. 
Only results from all statistics are presented in the table since pairs and all statistics provided similar 
results. 
 
Table 9. Sex-stratified linkage results.  
Sex-stratified linkage results on chromosome 20 for DSM-IV ND diagnoses 
 Study I A (N=759) Study I B (N=1,302) 
 Males N=188 Females N=149 Males N=313 Females N=235 
Marker Location LOD a LOD b LOD a LOD b LOD a LOD b LOD a LOD b 
D20S852 20p12.1 0.332 0.901 1.741 2.430 0.001 0.113 1.827 2.325 
D20S112 20p12.1 0.810 0.938 2.591 2.944 0.245 0.126 2.232 2.620 
D20S432 20p11.23 0.597 0.992 0.933 2.520 0.188 0.147 0.653 1.969 
D20S912 20p11.23 0.794 1.266 1.177 2.742 0.580 0.498 1.377 2.023 
D20S871 20p11.21 2.654 1.410 2.155 2.224 0.879 0.720 1.727 1.376 
D20S195 20q11.21 0.457 1.212 1.390 2.357 0.633 0.775 0.910 1.244 
D20S884 20q11.23 0.441 0.953 3.441 2.319 0.183 0.461 3.259 1.269 
D20S107 20q12 0.701 0.691 1.196 1.931 1.224 0.377 0.715 0.913 
D20S899 20q13.11 1.235 0.459 1.243 1.078 1.258 0.254 1.370 0.519 
 a LOD score from a singlepoint linkage analysis using all statistics; b LOD score from a multipoint linkage analysis 
using all statistics. Bolded values refer to statistifically significant LOD scores. 
Male-specific linkage signal peaks were seen from the same region as the signal for the pooled 
analyses in Study I A (See chapter 5.1.1). The analysis of the female group highlights a region at 
20q11.23, which harbors several genes in close proximity to marker D20S884. These genes include 
SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)), BLCAP (bladder cancer 
associated protein), and NNAT (neuronatin).
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In Study I B, an increase in the sample size resulted in findings similar to the Study I A results in 
females (N=650), because the evidence for linkage remained invariable at 20q11.23 (D20S884, 
MLOD 3.3 (singlepoint)) (Table 8). Figure 9 shows the single- and multipoint linkage results for 
females (A) and males (B). In males (N=652), singlepoint analysis yielded a modest MLOD score of 
1.3 at 20q13 with marker D20S899 (Table 8), and thus the suggestive evidence of linkage observed 
with marker D20S871 in a smaller sample in Study I A diminished. Nevertheless, these results clearly 
suggest that chromosome 20 harbors genetic elements which may influence sex differences in ND.  
 
Figure 9.  Study I B sex-stratified linkage results on chromosome 20, all statistics, in females (N=650) (A), and in 
males (N=652) (B). X-axis of the figures describes the marker location (cM) along chromosome 20; Y-axis presents 
the LOD score for each marker obtained from the linkage analyses. 
 
In the simulation analyses, the highest LOD score (single-point 3.3 in females) produced an empirical 
p-value of <0.001 in the permutation analyses based on 1,000 permutations. A LOD score this high 
(3.3) was not reached even once (highest LOD score obtained in the simulations for females was 3.2). 
None of the analyses yielded linkage near 20q13.2–q13.33, which harbors CHRNA4 encoding the 
nAChR subunit α4. However, the rather wide multipoint linkage signal peak detected approximately 
26 Mb upstream of CHRNA4 may indicate genetic elements in close proximity to CHRNA4. Hence, 
the role of CHRNA4 cannot be ruled out. In fact, a recent GWAS meta-analysis detected an 
association between a CHRNA4 splice site variant and ND measured by FTND (Hancock et al., 2015). 
The NAG-FIN sample was included in that study as a replication cohort. Since GWAS identify 
mainly common variants, it is not surprising that the linkage approach in Study I did not yield 
evidence of linkage close to CHRNA4. Whether the genes residing at 20q11.23 have an impact on 
sex differences in ND remains unsolved in this study, and further investigation with larger samples 
is required. In both Studies I A and I B the sample sizes of the sex groups are small, which may result 
in false positive signals. However, the linkage signal on the 20q11.23 region detected in the female 
group remains significant in Study I B, which strongly argues against a false positive finding. 
It is worth emphasizing that the linkage result on chromosome 20, predominantly driven by females, 
is captured by DSM-IV ND. The binary FTND measure did not yield any linkage in Studies I A or I 
B in either of the sex groups. FTND provides more accurate measures of pharmacological and
     
A B 
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physical dependence, while DSM-IV ND focuses more on the behavioral and cognitive layers of ND 
(DiFranza et al., 2010). Based on these arguments, and since females may be more prone to 
environmental smoking cues than males (Lynch 2009; Franklin et al., 2015), our sex-stratified results 
are consistent with the assumption of the differences between the two ND measures.  
5.1.3 Genome-wide association study for smoking behavior highlights 16p12.3 and 
11p15.5 (Study II) 
 
Chromosome 16p12.3 and a region near gene CLEC19A  
Owing to the scarce underlying genetic contribution for smoking behavior and ND, Study II aimed 
to identify novel genetic variants influencing smoking behavior in a Finnish twin family sample 
utilizing genotype data imputed using a 1000 Genomes Phase I reference panel (1000 Genomes 
Project Consortium, 2012) and Finnish population-specific reference panel from SISu project. In 
Study II, we conducted a GWAS to examine the impact of common and low-frequency variants on 
smoking behavior traits (N=1,715).  
Smoking quantity (both CPD and MaxCigs24) yielded genome-wide significant association on 
16p12.3, and thus strengthened our previously reported GWAS findings with an overlapping sample 
(a subset of 1,114 individuals from the current sample) (Loukola et al., 2014). The strongest 
association signal for CPD was detected with rs4300632 (P=8.5x10-9) and for MaxCigs24 with 
rs2353663 (P=7.0x10-9). Table 10 shows the top 20 association results for CPD. Beta coefficients are 
reported for minor alleles, creating a more meaningful approach for reporting the results. The 
association signal peaks from region chr16:19,326,020 – 19,357,771, and harbors altogether 23 
genome-wide significant SNPs. Also, according to conditional analysis, the association region 
harbors only one independent locus. Within the strongest association region on chr16:19,326,020 – 
19,357,771, the SNPs are in LD with each other (Figure 10).
  
65 
   
 
Table 10. Top 20 genetic variant results for cigarettes per day. 
Chr Positiona SNP Allele 1 Allele 2 p-value β SE MAF 
16 19350508 rs4300632 T A 8.5E-09 4.7 0.82 0.046 
16 19351749 rs11074386 T C 9.8E-09 4.7 0.82 0.046 
16 19355577 rs11074388 A G 1.1E-08 4.4 0.76 0.055 
16 19353064 rs916078 T C 1.2E-08 4.7 0.82 0.046 
16 19351837 rs11074387 G A 1.6E-08 4.4 0.77 0.055 
16 19352221 rs4782229 T C 1.6E-08 4.3 0.77 0.055 
16 19352463 rs916077 A G 1.8E-08 4.3 0.77 0.055 
16 19352499 rs2353661 A C 1.8E-08 4.3 0.77 0.055 
16 19353107 rs139902244 ATTATTACCCC A 1.9E-08 4.3 0.77 0.055 
16 19353159 rs762761 A G 1.9E-08 4.3 0.77 0.055 
16 19353246 rs762762 C T 2.0E-08 4.3 0.77 0.055 
16 19353328 rs4238673 C A 2.0E-08 4.3 0.77 0.055 
16 19353409 rs4782232 G A 2.0E-08 4.3 0.77 0.055 
16 19353429 rs4782233 C T 2.0E-08 4.3 0.76 0.056 
16 19353430 rs4782234 T C 2.0E-08 4.3 0.76 0.056 
16 19353940 rs2213280 A G 2.1E-08 4.3 0.77 0.055 
16 19352688 rs2353664 G A 2.3E-08 4.4 0.78 0.055 
16 19354089 rs2227005 T C 2.3E-08 4.3 0.77 0.055 
16 19352685 rs2353663 T G 2.4E-08 4.4 0.78 0.055 
16 19352684 rs2353662 C T 2.6E-08 4.4 0.78 0.055 
a Base pair position according to human reference sequence Build37/hg19 assembly  
Abbreviations: Chr, chromosome; SNP, single nucleotide polymorphism; Allele 1, effect allele (minor allele); Allele 
2, alternative allele (major allele); β, effect size provided by beta-value; SE, standard error; MAF, minor allele 
frequency.
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Figure 10. The linkage disequilibrium structure for genome-wide significant gene variants located in 16p12.3. Darker 
color indicates higher r2 values. In black columns, two SNPs are fully correlated. The green rs-number flags the 
strongest association signal for the self-reported cigarettes per day. 
 
The signal is located in an intergenic region, 28 kb from CLEC19A (C-type lectin domain family 19, 
member A); the function of which still lacks a more detailed description and has low levels of 
expression throughout the various tissues (gtexportal.org). It is possible that CLEC19A SNPs tag 
causal variants or regulatory motifs within this region, including neighboring genes SYT17 
(synaptotagmin XVII) and TMC5 (transmembrane channel-like 5). In fact, no eQTLs or meQTLs 
were seen for CLEC19A, since the gene was insufficiently expressed in the public databases. 
However, a majority of the 23 genome-wide significant SNPs were identified as eQTLs for genes 
SYT17 and TMC5 in brain tissue databases GTEx and BRAINEAC. Figure 11 summarizes the main 
results for the eQTL and meQTL search. It is no wonder that eQTLs are seen, since the association 
region is located on a DNAse I hypersensitivity site. These sites span approximately 42% of the 
human genome (Maurano et al., 2012). In these specific regions of the genome, chromatin has lost its 
condensed structure, exposing the DNA and making it accessible for DNA degradation enzymes, but 
also for increased transcriptional activity.
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Figure 11. A summary of the main findings from the expression quantitative trait loci 
(eQTL) and methylation quantitative trait loci (meQTL) analyses.  
 
The 16p12 locus has previously shown linkage with ADHD (Romanos et al, 2008), which is one of 
the most common neurodevelopmental disorders in childhood. ADHD has been associated with 
smoking in adulthood (Brook et al, 2008). Moreover, the locus 16p12.3 is not associated with cotinine 
(Ware et al., 2016), the primary metabolite of nicotine, suggesting that the signal is most likely driven 
by co-morbidity factors rather than genetic variants directly influencing inter-individual differences 
in smoking amount. Hence, the suggested co-morbidity effect cannot be ruled out.   
The 16p12.3 region has yielded evidence of linkage with MaxCigs24 (Han et al., 2010), whereas 
large-scale GWAS meta-analyses have not highlighted this locus (Saccone et al, 2010; Liu et al, 2010; 
Thorgeirsson et al, 2010; Tobacco and Genetics Consortium, 2010). The associating variants on the 
16p12.3 locus are low-frequency variants (MAF 0.04-0.06) that produce remarkably large effects 
(Table 9), corresponding to an increase in smoking quantity of approximately five cigarettes per day, 
with respect to each minor allele at the locus. When these effect sizes are compared with the ones 
produced by the most well-established smoking quantity locus at 15q25.1 (tagged by rs16969968), 
which corresponds to an increase of only one CPD, the effects captured by 16p12.3 locus variants are 
large. However, the MAFs between the variants on these two loci vary significantly, the MAF for 
rs16969968 is 0.32 (in the large Finnish population sample utilized in Study III), while the genetic 
variants on the 16p12.3 association region are low-frequency variants. Hence, the impact of the 
polymorphisms in the 16p12.3 region is less notable at the population level. However, in the sample 
used in Study II, the minor allele of variant rs4300632 was well-represented, with altogether 157 
copies of the minor allele being found among the 1,714 smokers included in the study. A boxplot in 
Figure 12 shows the large effect of variant rs4300632 on CPD.
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Figure 12. A boxplot of the rs4300632 (on 16p12.3) genotype 
distribution among smokers. The number of individuals carrying 
0, 1 and 2 copies of the minor allele were 1,560, 151 and 3, 
respectively.  
 
The data in Study II was imputed using the 1000 Genomes Project reference panel Phase 1 (1000 
Genomes Project Consortium, 2012) together with a low-pass whole genome sequence-based Finnish 
panel from the Sequencing Initiative Suomi project, whereas the data used in the previous work 
(Loukola et al., 2014) was imputed using the HapMap2 reference panel. In order to determine whether 
the gain of strength in the association signal is due to a mere increase in the sample size or a result of 
a higher imputation quality, the association region of 16p12.3 was scrutinized in parallel using three 
data sets from the same sample with different imputation reference panels: HapMap2, 1000 Genomes 
Phase 1, and 1000 Genomes Phase 1 + SISu. The comparison showed an increase in the number of 
SNPs included in the association region (HapMap2: 526 SNPs, 1000 Genomes Phase 1: 1,282 SNPs, 
and 1000 Genomes + SISu: 1,304 SNPs). Despite differences in numbers of SNPs, and their 
imputation quality scores, the association signals in the different data sets map to exactly the same 
region. This result suggests that the increase in the strength of the association is due to merely an 
increase in the power, enabled by the larger study sample.    
 
Neurotrophin signaling pathway 
Although the function of CLEC19A remains undetermined, an intriguing and established transcription 
factor binding site (TFBS) is located at the position chr16:19,328,414 – 19,328,427, which stands 
within the association locus (chr16:19,326,020 – 19,357,771). This TFBS serves as a binding site for 
nuclear factor κ B (NF-κB) transcription factors (genome.ucsc.edu). NF-κBs are a conserved family 
of pleiotropic transcription factors operating, for example, in the immune system through the 
regulation of immune and inflammatory responses triggered via Toll-like receptors (Medzhitov 
 
  
69 
   
 
2001). Additionally, they are involved in complex pathways that regulate synaptic plasticity (Mattson 
and Meffert, 2006). One of these pathways, the neurotrophin signaling pathway, include 
neurotrophins (Mattson and Meffert, 2006), which have important roles in neural development (Bibel 
and Barde, 2000). Thus, it is a promising addition to the scarce list of candidates affecting the inter-
individual differences in smoking behavior.  
In Study II, a GWAS was performed in order to confirm and discover novel target genes and factors 
predisposing smokers to sustain the smoking behavior. This aim was achieved by strengthening a 
previously reported finding of association near CLEC19A with smoking quantity, and further linking 
the finding with the neurotrophin signaling pathway through the TFBS for NF-?B transcription 
factors. This pathway is not a novel discovery in smoking-related research. In fact, previous studies 
have reported association between the neurotrophin signaling pathway and smoking-related traits: 
smoking initiation and progression (Lang et al, 2007; Tobacco and Genetics Consortium, 2010; Wang 
and Li, 2010), and smoking cessation (Wang and Li, 2010). However, these findings targeted and 
highlighted only a couple of members of the pathway, BDNF and NTRK2. In Study II, no association 
was detected with either of these genes. Thus, further studies are required in order to verify the result 
and the plausible link between smoking behavior and the neurotrophin signaling pathway.  
 
 
Figure 13. A regional plot of the genome-wide association study for DSM-IV NW symptom 
count showing association on 11p15.5.
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In addition, an intriguing association signal supporting the role of the neurotrophin signaling pathway 
was observed with the DSM-IV NW symptom count, with locus 11p15.5 showing association 
approaching genome-wide significance (P=6.58x10-8) for rs369708413. This locus harbors several 
genes, which are illustrated in Figure 13. The signal peaks at AP2A2 (adaptor-related protein complex 
2, alpha 2 subunit) and MUC6 (mucin 6). Adaptor-protein 2 (AP-2) is an important mediator in 
endocytic vesicle formation, together with clathrin (Smythe, 2002), and is involved in the 
neurotrophin signaling pathway (Beattie et al., 2000). The other gene, MUC6, is up-regulated by 
NFκB1 (Sakai et al., 2005). In addition, the top MUC6 variant, rs201137338 (P=4.2x10-7), is a 
missense variant (H524Q), which changes histidine to glutamine, consequently changing the 
electrically-charged sidechain into a polar uncharged sidechain. Thus, this polymorphism is a 
functional variant, with a potential capability of altering the end product through an impaired folding 
of the polypeptide. The association results for DSM-IV NW highlighting locus 11p15.5 are presented 
in Table 11.  
 
Table 11. Association results for DSM-IV NW on locus 11p15.5. 
Chr Positiona SNP Allele 1 Allele 2 p-value β SE MAF 
11 920049 rs561547189 A G 9.9E-07 1.34 0.27 0.018 
11 941391 rs529797424 C T 6.3E-07 1.37 0.27 0.018 
11 983584 rs369708413 C T 6.6E-08 1.61 0.30 0.017 
11 993507 rs560149619 A G 1.7E-07 1.50 0.28 0.017 
11 1028665 rs201137338 G C 4.2E-07 1.40 0.27 0.018 
a Base pair position according to human reference sequence Build37/hg19 assembly  
Abbreviations: Chr, chromosome; SNP, single nucleotide polymorphism; Allele 1, effect allele (minor 
allele); Allele 2, alternative allele (major allele); β, effect size provided by beta-value; SE, standard 
error; MAF, minor allele frequency. 
 
Another interesting gene, DRD4 (dopamine receptor D4), is located approximately 343 kilobases 
upstream from the association signal. The DA system has been under close investigation in smoking-
related research (Moran et al, 2013; George and O’Malley 2004; Picciotto 2003), making DRD4 an 
important candidate gene in smoking behavior. It encodes the D4 subtype of the DA receptor, and 
thus plays an important role in processes in which the highly rewarding effect of DA is pivotal, such 
as learning and memory (Wise, 2004). Both are essential in the development of smoking behavior 
and ND.  
Previous linkage studies have highlighted the connection between locus 11p15 and smoking-related 
traits. Pergadia and colleagues (2009) yielded genome-wide significant linkage of the locus with 
DSM-IV NW using a subset of 505 individuals from the Study II sample. Also, linkage has been 
detected with DSM-IV ND, FTND, and a co-morbid phenotype of ND and alcohol use (Loukola et 
al, 2008). Additionally, the same locus has shown genome-wide significant association with chronic 
bronchitis, which is one of the classic phenotypes of COPD (Lee et al, 2014). These previous reports, 
combined with the results observed in Study II, clearly suggest that locus 11p15 harbors an element 
or possibly several elements that influence the occurrence of smoking-related traits. DRD4 plays an 
undisputable role in smoking behavior, at least in theory, though solid evidence of association is still 
lacking using the GWAS approach. Study II, like so many other GWASs, detected no association 
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with variants located in the close vicinity of DRD4, but instead highlighted other genes (AP2A2 and 
MUC6) within the region, which have links to the neurotrophin signaling pathway.  
The variants in the 11p15.5 region are more frequent in Finland than other European populations, 
which is likely due to the Finnish population history of founding bottlenecks. Thus, the genetic 
background of the Finnish population offers a clear advantage for studying low-frequency and rare 
variants (Surakka et al. 2016). It is worth emphasizing that this study highlights genetic variants (in 
close proximity to CLEC19A, and within AP2A2 and MUC6) that have low MAFs. The associating 
variants and their allele frequencies in the study sample and in other populations are compared in 
Table 12.   
 
Table 12. Genetic variants highlighting the neurotrophin signaling pathway - a global comparison of minor 
allele frequencies.  
     MAF 
SNP Positiona Chr Allele 1 Allele 2 Sample CEUb YRIb JPTb 
rs369708413 983584 11 C T 0.017 0.005 0.009 0 
rs560149619 993507 11 A G 0.017 0 0 0 
rs201137338 1028665 11 G C 0.018 0 0 0 
rs4300632 19350508 16 T A 0.046 0.04 0 0.337 
rs11074386 19351749 16 T C 0.046 0.04 0 0.337 
rs11074388 19355577 16 A G 0.055 0.04 0.352 0.438 
a Base pair position according to human reference sequence Build37/hg19 assembly; b Allele frequencies 
have been obtained using publicly available database Ensembl (ensembl.org) 
Abbreviations: SNP, single nucleotide polymorphism; Chr, chromosome; Allele 1, effect allele (minor allele); 
Allele 2, alternative allele (major allele); MAF, minor allele frequency; CEU, Utah residents with Northern 
and Western European ancestry; YRI, Yoruba in Ibadan, Nigeria; JPT, Japanese in Tokyo, Japan. 
 
The results in Study II highlight factors which are involved in the neurotrophin signaling pathway. 
This suggests that the pathway might regulate neuronal modifications that have a plausible impact on 
the sustained use of tobacco products.   
 
No genome-wide significant association for DSM-IV ND 
The GWAS performed in Study II included DSM-IV ND and aimed to discover novel genetic variants 
predisposing individuals to ND, and also to confirm previous suggestive findings of association 
reported in an earlier GWAS (Loukola et al., 2014). Despite the well-known reputation of DSM-IV 
to provide efficient tools for classifying and diagnosing currently recognized mental disorders, 
including substance-related disorders, DSM-IV ND is remarkably underutilized in research studies. 
The NAG-FIN sample used in Studies I and II remains one of the few to include DSM-IV-classified 
disorders and traits (ND, NW, and alcohol dependence). The inclusion of distinct measures and tools 
for capturing smoking as a behavior has assisted in creating a sample consisting of unique and highly 
detailed phenotype profiles. 
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Table 13. Top 10 GWAS results for DSM-IV ND. 
Chr Positiona SNP Allele 1 Allele 2 p-value β SE MAF 
5 5786702 rs187632 A G 7.2E-07 -0.09 0.02 0.462 
11 21472503 rs148586747 A G 7.4E-07 -0.27 0.05 0.027 
7 19566286 rs6461441 C A 8.5E-07 -0.12 0.02 0.156 
7 19554431 rs2192487 G A 8.7E-07 -0.12 0.02 0.152 
7 19563837 rs2192483 G A 1.1E-06 -0.12 0.02 0.151 
7 19573641 rs17141561 C T 1.3E-06 -0.12 0.02 0.155 
14 99275537 rs188595723 G A 1.9E-06 0.31 0.06 0.020 
10 99790398 rs61873668 G C 2.4E-06 -0.11 0.02 0.167 
7 19569253 rs7796093 C A 2.6E-06 -0.12 0.02 0.147 
4 15542197 rs16892135 G A 2.9E-06 0.10 0.02 0.218 
a Base pair position according to human reference sequence Build37/hg19 assembly  
Abbreviations: Chr, chromosome; SNP, single nucleotide polymorphism; Allele 1, effect allele (minor 
allele); Allele 2, alternative allele (major allele); β, effect size provided by beta-value; SE, standard error; 
MAF, minor allele frequency. 
 
The study did not yield genome-wide significant association with DSM-IV ND. The results of DSM-
IV ND diagnosis are presented in Table 13. In the previous study (using a subset of 1,114 individuals 
from the current sample), DSM-IV ND diagnosis showed a suggestive association (min P=1.68x10-
6) on 2q33, harboring a neuregulin receptor ERBB4 (Loukola et al, 2014). Furthermore, evidence of 
linkage has previously been reported on 2q33 with a regular smoker phenotype, using a subset of 505 
individuals from the current sample (Loukola et al, 2008). Although the sample size in the current 
study was increased compared to the previous GWAS, no statistically significant association was 
detected for ERBB4 (P=1.0x10-4 for ND diagnosis; P=9.5x10-5 for ND symptom count). There are a 
few plausible explanations for this. First, a false positive finding in the previous GWAS cannot be 
ruled out. However, Turner and colleagues (2014) highlighted the connection between ERBB4/NRG3 
signaling and ND and NW using both behavioral mouse models and association analyses in a clinical 
trial sample, providing further evidence for the involvement of ERBB4 in smoking behavior. Second, 
although sample size was increased, the current sample was diluted with respect to the prevalence of 
ND. In the previous GWAS, 592 out of the 1,114 subjects (54%) fulfilled the DSM-IV ND criteria 
and scored, on average, 3.0 on the symptom scale, whereas among the 601 subjects added to the 
current study, 281 (47%) fulfilled the criteria and scored, on average, 2.6 on the symptom scale (t-
test p-value < 0.0001). Similarly, smoking quantity differs between the previous sample (average 
CPD of 19.7) and the additional subjects (average CPD of 17.4). Third, the previous GWAS analyses 
were done with the Plink QFAM algorithm, which differs from the linear mixed model used in the 
current study. 
5.1.4 The strongest genetic evidence for smoking behavior (Study III) 
 
While the broad picture of smoking behavior and ND is known, the basis for underlying molecular 
genetics remains in its early steps. Only one locus, 15q25.1, has proved solid evidence for association 
with smoking-related traits and diseases in several independent studies, large-scale GWASs, GWAS
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meta-analyses, and replication studies (Saccone et al., 2010; Thorgeirsson et al., 2010; Liu et al., 
2010; Tobacco and Genetics Consortium (TAG) 2010; Amos et al., 2008; Hung et al., 2008). 
Chromosome 15q25.1 harbors the CHRNA5-CHRNA3-CHRNB4 gene cluster, encoding the nAChR 
subunits α5, α3, and β4. Study III aimed to replicate the reported finding between three distinct loci 
at 15q25.1 and smoking quantity (Saccone et al., 2010) in a large Finnish population-based sample. 
In addition, Study III provided precise estimates of the strength of the association in the Finnish 
population.   
We utilized the National FINRISK study and the Health 2000 Survey samples, and grouped smokers 
into heavy smoking “cases” (CPD>20) and light smoking “controls” (CPD≤10), thus generating a 
dichotomous CPD variable. The associations between dichotomous CPD and locus 1 (rs16969968, 
prevalence odds ratio (OR)=1.39, P=1.43 x 10-9) and locus 2 (rs578776, OR=0.80, P=0.00005) were 
successfully replicated, but the analyses for the dichotomous trait did not yield statistical significance 
for locus 3 (rs588765, OR=0.91, P=0.091). However, the association between smoking quantity and 
locus 3 was detected with quantitative CPD (β=0.023, P=0.036), but only after adjusting for 
rs16969968 (locus 1). This result is in line with a previous finding reported by Saccone and colleagues 
(2010). The results for both dichotomous and quantitative CPD are presented in Table 14. These 
results likely reflect the differences in power; 8,356 current smokers were included in the quantitative 
CPD variable, while the dichotomous CPD variable consisted of 3,624 controls and 1,076 cases.  
 
Table 14. Single-SNP association results of dichotomous and quantitative CPD analyses. 
 Dichotomous CPD (N=4,700) Quantitative CPD (N=8,356) 
 Logistic regression Negative binomial regression 
Single-SNP analysis OR 95% CI p-value β 95% CI p-value 
rs16969968 1.39 1.25,1.55 1.43 x 10-9 0.067 0.048,0.086 1.11 x 10-12 
rs578776 0.80 0.72,0.90 0.00005 -0.042 -0.061,-0.023 6.50 x 10-6 
rs588765 0.91 0.81,1.01 0.091 -0.020 -0.038,-0.002 0.028 
Joint model analysis OR 95% CI p-value β 95% CI p-value 
rs16969968 1.34 1.18,1.52 2.56 x 10-6 0.062 0.040,0.083 7.14 x 10-9 
rs578776 0.93 0.81,1.06 0.262 -0.012 -0.034,0.009 0.266 
rs16969968 1.49 1.30,1.70 1.43 x 10-9 0.081 0.058,0.104 8.95 x 10-13 
rs588765 1.13 0.99,1.29 0.066 0.023 0.001,0.045 0.036 
CPD, cigarettes per day; OR, Odds Ratio; CI, confidence interval; β, effect size provided by beta-value. 
 
Interestingly, three other meta-analyses conducted by large consortia have been unsuccessful in 
detecting confirmatory evidence of association for rs588765 (locus 3) and smoking quantity 
(Thorgeirsson et al., 2010; Liu et al., 2010; TAG 2010). Methodological differences could provide a 
plausible explanation for this discrepancy. Saccone and colleagues (2010) used logistic regression in 
their analyses to test for association with dichotomous CPD, while the three other meta-analyses used
Results and discussion 
 
 
74 
   
 
linear regression and analyzed either quantitative or categorical CPD (Thorgeirsson et al., 2010; Liu 
et al., 2010; TAG 2010). In Study III, the associations between quantitative CPD and the three loci, 
including locus 3 (rs588765), were detected using negative binomial regression.  
 
Table 15. Estimated number of cigarettes smoked per day, stratified by genotypes of three single nucleotide 
polymorphisms. 
CPD, cigarettes per day; CI, confidence interval. 
 
The most well-established locus within the 15q25.1 region is tagged by the functional SNP 
rs16969968. The variant has been suggested to contribute to increased nicotine consumption by 
impairing the capacity of (α4β2)α5 nAChRs to produce a normal inhibitory motivational signal 
intended to limit nicotine intake (Fowler et al., 2011). In Study III, precise estimates of the strength 
of association were provided for each locus tagged by SNPs rs16969968, rs578776 and rs588765. 
Notably, the effect size of rs16969968 was approximately one CPD for each minor allele (Table 15), 
in agreement with the original GWAS report by Thorgeirsson and colleagues (2008). 
Smoking and alcohol use frequently co-occur, resulting in high correlation between the two traits 
(Dani and Harris, 2005). Hence, in order to determine the specificity of the three loci, the CPD 
analyses were adjusted for log-transformed alcohol consumption in an additional model. The results 
showed remarkable similarity with and without the adjustment for alcohol use. The lack of difference, 
specifically in locus 1, suggests that the association signal from rs16969968 is specific to smoking. 
A previous study supports this finding (Wang et al., 2009), since no evidence of association was 
observed between alcohol dependence and rs16969968, while the effect of the SNP’s specificity to 
smoking was confirmed.   
On chromosome 15q25.1, two distinct loci have been consistently highlighted in smoking-related 
research: locus 1, tagged by rs16969968 or rs1051730 (a highly correlating SNP located on 
CHRNA3), and locus 2, tagged by rs578776. Study III, along with several other association studies, 
suggests that locus 1 is a risk factor for smoking behavior with the minor allele predisposing an 
individual to smoking behavior. Although the effect of locus 1 is undeniably robust throughout 
different populations, the effect of the minor allele corresponds to merely a small increment in the 
daily smoking quantity. Locus 2, on the other hand, seems to have a protective effect on smoking, 
with an OR of 0.8 being reported in Study III. This result is consistent with previous reports (Saccone 
et al., 2010). Lastly, the role of an additional distinct locus 3 (tagged by rs588765) in smoking 
behavior remains unconfirmed, since an association signal was detected with quantitative CPD only 
after adjusting for rs16969968, but the dichotomous trait failed to achieve statistical significance.
Locus 15q25.1 N of minor alleles per genotype 
0 1 2 
SNP mean CPD  95% CI mean CPD 95% CI mean CPD 95% CI 
rs16969968 13.9 13.6, 14.2 14.8 14.5, 15.1 16.0 15.4, 16.6 
rs578776 14.9 14.7, 15.2 14.2 13.9, 14.5 13.9 13.9, 14.5 
rs588765 14.8 14.5, 15.1 14.3 14.0, 14.6 14.4 13.9, 14.9 
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5.2. Pleiotropic effects of nAChR subunits 
 
5.2.1 Association of the α5-α3-β4 subunit cluster with alcohol use 
 
The CHRNA5-CHRNA3-CHRNB4 gene cluster on chromosome 15q25.1 has been thoroughly 
scrutinized in research with smoking-related traits and diseases. Altough smoking often co-occurs 
with alcohol use, and growing evidence from animal and human studies suggest that different drugs 
of abuse utilize a common circuitry in the brain’s limbic system (Nestler, 2001; Di Chiara et al., 2004; 
Pierce and Kumaresan, 2006; Ross and Peselow, 2009; White and White, 2016), only a few studies 
have explored the 15q25.1 locus with alcohol-related traits. Clearly, further studies are required to 
define the role of genetic variants in the nAChR genes contributing to inter-individual differences in 
alcohol use. In Study III, the goal was to examine the role of genetic variants on this robust smoking 
behavior locus in alcohol use, and to investigate whether such a role is independent of smoking. 
In Study III, association was tested between three SNPs, rs16969968, rs578776, and rs588765, and 
alcohol use. The trait was analyzed as quantitative, categorized and dichotomized alcohol use. Out of 
all the distinct association analyses, only dichotomous alcohol use, defined as ‘abstainers and low-
frequency drinkers’ (N=12,246) vs. ‘drinkers’ (N=19,566) yielded a statistically significant 
association with rs588765 (locus 3, OR=1.15, P=0.00007). Table 16 shows the logistic regression 
association results for the binary alcohol use variable. Individuals with a homozygous genotype for 
the minor allele were more likely to be drinkers. No evidence of association was detected with the 
quantitative or categorical alcohol use traits.  
 
Table 16. Results for logistic regression analyses of binary alcohol use 
(abstainers and low-frequency drinkers vs. drinkers).  
SNP N of minor alleles OR 95% CI p-value 
rs16969968 
0 REF   
1 0.93 0.89,0.98 0.007 
2 0.97 0.89,1.05 0.430 
rs578776 
0 REF   
1 0.98 0.94,1.03 0.532 
2 0.98 0.90,1.06 0.569 
rs588765 
0 REF   
1 1.00 0.95,1.05 0.945 
2 1.15 1.07,1.24 0.00007 
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; 
REF, reference. 
 
Evidence of association has been reported between locus 1 (rs16969968) and symptoms of alcohol 
abuse or dependence (Chen et al., 2009). Also, association signals have been detected from locus 2 
(rs578776) and locus 3 (rs615470) with DSM-IV alcohol dependence in an African-American 
sample, while in the same study, samples of European decent provided no evidence of association 
(Sherva et al., 2010). In another study, Wang and colleagues (2009), reported association between
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DSM-IV alcohol dependence and locus 3 (rs588765), whereas their study, in unison with Study III, 
detected no association with either locus 1 rs1696968 or locus 2 rs578776. On top of the works 
focusing on alcohol dependence, association has been reported between alcohol use initiation in 
young Americans of European descent and two SNPs (rs1948 and rs11634351) located on CHRNB4 
(Schlaepfer et al., 2008). The accumulating amount of contradicting evidence in study results may 
partly reflect population heterogeneity and different LD structures in different study samples.  
It is worth noting that abstainers and low-frequency drinkers form a truly heterogeneous group of 
subjects. The group potentially includes some participants who are former alcoholics, but are 
abstaining at the time of the data collection. These former alcoholics bring a possible confounder 
aspect to the study, which was addressed by repeating the analysis among never smokers. Due to the 
established co-occurrence between alcoholism and heavy smoking, it is unlikely that many former 
alcoholics are included in the analysis restricted to never smokers. In addition, this approach excludes 
the possibility of confounding in the association signal emerging from smoking. Intriguingly, limiting 
the analysis to never smokers, thus narrowing the total sample size to 16,786 individuals, had no 
notable impact on the effect of locus 3 (OR=1.18, P=0.001) (Table 17).  
 
Table 17. Results for logistic regression analyses of binary alcohol use among 
never smokers (abstainers and low-frequency drinkers vs. drinkers).  
SNP N of minor alleles OR 95% CI p-value 
rs16969968 
0 REF   
1 0.96 0.90,1.03 0.230 
2 0.95 0.85,1.06 0.368 
rs578776 
0 REF   
1 0.96 0.90,1.03 0.271 
2 0.93 0.84,1.04 0.217 
rs588765 
0 REF   
1 1.04 0.97,1.12 0.231 
2 1.18 0.97,1.12 0.001 
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; 
REF, reference genotype. 
 
This strongly suggests that the association signal detected with variant rs588765 is specifically 
produced by regular alcohol use. Although the effect of locus 3 is somewhat modest, this result 
confidently provides new direction for the entire body of research of locus 3 in the CHRNA5-
CHRNA3-CHRNB4 gene cluster suggesting that the effects of alcohol use may, at least to some extent, 
be mediated through nAChRs and their downstream transmitters. In fact, the most studied transmitter 
molecule system is the mesolimbic DA pathway, which consists of dopaminergic neurons and their 
targets (Nestler, 2005). This pathway links several brain regions, and some of them are involved in 
the brain’s natural memory system. Notably, powerful emotional memories have further been 
hypothesized as an important aspect resulting in addictive behaviors (Wise, 2004; Everitt et al., 2003). 
The emotional effects of natural rewards, such as food and social interactions, may be mediated by 
the DA system (Kelley and Berridge, 2002; Tobler et al., 2005). nAChRs are closely linked to this 
system, and thus they may mediate responses to other substances and natural rewards. Emerging 
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evidence from rodent studies indicate that ethanol interacts with nAChRs in the dopaminergic reward 
circuitry to affect brain reward systems (Nestler, 2005; Hendrickson et al., 2013).  
These results from Study III provide highly welcomed fragments of evidence explaining the 
molecular genetic basis underlying the shared genetic predisposition between smoking and alcohol 
use, which has largely been unknown. Thus, these results suggest that nAChR genes contribute, not 
only to inter-individual differences in smoking, but in alcohol use as well. 
 
5.2.2 Causality between smoking and BMI (Study IV) 
 
Cigarette smoking is a modifiable environmental factor among many others that has a strong lifestyle 
influence on BMI. Consistent results from epidemiological studies show that smokers have a lower 
BMI than non-smokers (Sneve and Jorde, 2008; Munafo et al., 2009). Questions of whether this 
association is causal (i.e., exposure to smoking causes lower BMI) can be addressed and investigated 
using the Mendelian Randomization approach. Indeed, stratification by smoking status has been 
reported to modify the association between rs1051730 (a genetic variant on 15q25 in complete LD 
with rs16969968) and BMI (Freathy et al., 2011). This result strengthens the evidence of causality 
between smoking and lower BMI. Study IV aimed to extend these findings by increasing the sample 
size from 24,198 (Freathy et al., 2011) to 148,730 (Taylor et al., 2014 (Study IV)), thus ensuring 
increased power for the analyses. Hence, a large-scale international meta-analysis was conducted by 
the Causal Analysis Research in Tobacco and Alcohol (CARTA) consortium 
(http://www.bris.ac.uk/expsych/research/brain/targ/research/collaborations/carta/), and the National 
FINSIRK study sample (N=20,368), including 5,120 current smokers, 5,493 formers smokers, and 
9,755 never smokers, was included in the analyses.  
 
Table 18. Association results of rs16969968a with body mass index, stratified by smoking 
status: a Mendelian randomization analysis. 
Smoking status N  Effect  
(% change in BMI) 
95% CI p-value 
Current smokers 38,912 -0.74 -0.97, -0.51 2.00x10-10 
Former smokers 43,009 -0.14 -0.34, 0.07 0.19 
Never smokers 66,809 0.35 0.18, 0.52 6.38x10-5 
Total 148,730 -0.07 -0.19, 0.04 0.22 
a or rs1051730, which is in full LD with rs16969968; BMI; body mass index; CI, confidence 
interval. 
 
The total sample size of the Mendelian Randomization analysis comprised altogether 148,730 never, 
former and current smokers. Among never smokers (N=66,809), a positive association was observed 
between the genetic variant (rs16969968 or rs1051730 depending on the cohort) and BMI, and the 
results are presented in Table 18. The result indicates a 0.35% increase in BMI per minor allele (95% 
CI 0.18, 0.52; P=6.38x10-5). In addition, this study confirmed the expected inverse association 
between the genetic variant and BMI in current smokers (N=38,912) (Table 18), indicating a 0.74% 
decrease in BMI per minor allele (95% CI -0.97, -0.51; P=2.00×10-10). The result is consistent with a 
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causal, anorexic effect of smoking on BMI. Former smokers (N=43,009) provided no evidence of 
association (percentage change -0.14, 95% CI -0.34, 0.07; P=0.19). Furthermore, an interaction of 
the estimates was tested, and they differed significantly from each other (P=4.95x10-13). In addition, 
the effects observed between smoking status and BMI were not modified by sex. Heterogeneity 
between the 29 cohorts included in the meta-analysis was low. It is critical to note that when the data 
was examined without stratification by smoking status no clear association was detected between 
rs16969968 and BMI (P=0.22), suggesting that a conventional GWAS using BMI as the phenotype 
of interest would have failed in detecting this signal. However, smoking status was not adjusted for 
in this additional test. 
The observed 0.35% increase per minor allele in BMI among never smokers represents a change of 
approximately 0.09 kg/m2. This change is rather small when compared to the effect of FTO (fat mass 
and obesity associated) gene variants (~0.4 kg/m2) (Frayling et al., 2007). However, the proportion 
of variance is comparable to the other variants identified for BMI (Speliotes et al., 2010). 
In Study IV, evidence of association for smoking cessation was observed (current vs. former smokers: 
OR per minor allele 1.08, 95% CI 1.06, 1.10; P=1.44x10-12), whereas, the data yielded no association 
for smoking initiation (ever vs. never smokers: OR per minor allele 1.01, 95% CI 0.99, 1.03; P=0.50). 
These results are consistent with previous studies which have reported that the rs16969968/rs1051730 
variant does not influence the ultimate risk of being a smoker (TAG, 2010), but it has been associated 
with short-term smoking cessation in treatment-seeking smokers (Munafo et al., 2011), suggesting a 
pleiotropic effect for the variant.  
These results indicate that rs16969968 may predispose never smokers to higher BMI in a manner 
similar to how it increases the risk for smoking heaviness among current smokers. At present, the 
exact mechanism through which the variant may induce a positive effect on BMI among never 
smokers remains uncertain, and can merely be speculated. In addition, the 15q25 region has provided 
evidence of pleiotropy (i.e., also being associated with other diseases or traits), since GWASs have 
established the association between the CHRNA5-CHRNA3-CHRNB4 gene cluster and smoking 
heaviness, as well as downstream health consequences, such as lung cancer and peripheral artery 
disease (TAG, 2010; Li et al., 2010, Thorgeirsson et al., 2010; Amos et al., 2008). On top of these 
results, candidate gene studies have suggested an association with cocaine use (Grucza et al., 2008) 
and alcohol use (Study III, see 5.2.1), as well as alcohol dependence (Sherva et al., 2010). Therefore, 
it can be hypothesized that nAChRs play a role in mechanisms that mediate responses to rewarding 
stimuli in general. Another possibility is that nAChR subunits play a direct role in mediating food 
intake, since evidence from animal models indicates that activation of hypothalamic α3β4 nAChRs 
initiates the activation of pro-opiomelanocortin neurons and triggers further, subsequent activation of 
melanocortin 4 receptors, which have proved to be critical for nicotine-induced decreases in food 
intake (Mineur et al., 2011). However, the exact mechanism for mediating food intake through 
nAChRs remains yet unspecified. It is worth noting that the effects observed in Study IV among 
current and never smokers may operate via other genes (namely CHRNA3 and CHRNB4) and their 
variants in LD with rs16969968. Clearly, further work, with possibly more detailed body composition 
measures, such as percent body fat and its distribution, is required to explore the causality and 
mechanism.  
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The association observed in never smokers was detected merely due to stratification by smoking 
status. Hence, if confirmed, these results will provide an important implication for future GWAS and 
their design, since additional variants may be identified using the GWAS approach when the known 
environmental exposures with pronounced effects on the phenotype of interest are stratified. 
To conclude, the pleiotropic effect of rs16969968 (or other variants in full LD) influences BMI. The 
results of Study IV demonstrate how the stratification of well-characterized environmental factors 
with a known impact on health outcomes may reveal novel genetic association with health outcomes. 
Accordingly, these associations may operate through genetic influences on the environmental factors 
themselves, or via other pathways which are veiled by the environmental factors.  
 
5.3 Strengths and Limitations 
 
The sample utilized in Studies I and II is a unique combination of highly detailed profiles describing 
broad substance use behaviors in a family setting. At the same time, the sample is limited by the low 
number of participating parents, leading to incomplete family structures, and thus, decreased power 
in family-based analysis. When the data was collected, the mean age of the twins was 57 years, which 
is why the majority of parents were unavailable. In addition, biochemical verification of the smoking 
status was not assessed with cotinine or exhaled carbon monoxide measurements. However, in our 
analyses only self-reported smokers were included; it is unlikely that many non-smokers would have 
claimed to be smokers in the extensive interview.  
While comparing Study II GWAS results with a previous GWAS using a subsample of the NAG-FIN 
sample (Loukola et al., 2014), a clear difference in the two sample sets was observed, but the direction 
of the difference was inconsistent between study phenotypes. Increasing the sample size with mainly 
siblings strengthened the CPD association findings, while the previously detected effects observed 
with DSM-IV ND diminished, which may have resulted in diluted variable variance in the sample. 
This is in line with the study design of the NAG-FIN sample: twin pairs concordant for heavy smoking 
were initially identified and used in our previous GWAS; in the current study, all available family 
members were also included. Family members included heavy smokers and light smokers, as well as 
non-smokers (which were excluded from the GWAS). It is plausible that some of the less exposed 
subjects may not have developed ND, but would do so given additional exposure; yet, since they are 
first degree relatives of the twins used in the original GWAS, there is a 50% probability that they 
carry the same risk alleles. Having risk allele carriers who have not yet developed ND reduces the 
power to detect the association. 
In Study I, both single-point and multipoint linkage analyses were performed. Unlike single-point 
analyses, multipoint analysis uses haplotype information from several markers to infer the IBD 
relationships (Halpern and Whittemore, 1999), and thus should increase power. However, cautious 
interpretation of the results is recommended since multipoint analysis has been suggested to be 
sensitive to power loss due to misspecification of intermarker order and distances, especially with 
closely spaced markers (Halpern and Whittemore, 1999). 
Results and discussion 
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In Study III, the likely absence or underrepresentation of severely alcohol and nicotine addicted 
individuals needs to be acknowledged. Although the sample is adequately sized and genetically 
homogenous, these highly addicted individuals are unlikely to participate in health-related surveys in 
the first place. However, their absence is unlikely to explain the novel association results with alcohol 
use.  
The outcome of smoking quantity in Study III differs from the one utilized in Studies I and II. This 
is due to phenotyping techniques in different samples. The NAG-FIN sample has been enriched for 
ND, and thus the criteria for qualifying as an ever smoker has been set high, 100+ cigarettes in the 
individual’s lifetime. However, the Finnish population-based samples used in Studies III and IV are 
large-scale health surveys, without any detailed emphasis on smoking. Thus, any participant reporting 
information on smoking quantity were qualified for the analyses. Hence, the sample size was ensured 
to be as large as possible to gain power. Therefore, the difference in measuring CPD must be 
acknowldeged when interpreting the results. 
The study design in Study IV, using Mendelian Randomization to detect causality between smoking 
and BMI, did not attempt to stratify smoking status according to smoking quantity or cotinine values, 
which could have possibly been a more informative and reliable measure of smoking status. Instead, 
the stratification relied solely on self-report. 
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6 CONCLUSIONS AND FUTURE PROSPECTS 
 
This thesis aimed to identify specific genes that would predispose individuals to smoking behavior 
and increased vulnerability to ND. Specifically, this study assessed genetic variants and their ability 
to explain the differences in smoking behavior between individuals. Considering the high heritability 
estimates of ND, the rationale to expect a genetic contribution was clear. 
Study I provided further evidence for chromosome 20 harboring genetic elements that do affect ND. 
In addition, Study I highlighted a significant sex-difference in the genomic regions linked to ND. The 
exact gene, be it a single genetic variant or several, however, remaines unidentified after this study, 
and requires additional research focusing, for example, on whole-genome sequence analyses. Also, 
whether the genes residing at the linkage loci have an impact on sex differences in ND remains 
unsolved. Follow-up studies with an epigenetic approach would assist in describing the detailed 
epigenetic profiles that may be involved in causing sex differences in ND, since the possibility of 
gene-environment interaction cannot be ruled out. In addition, ND variables in future studies would 
benefit from inter-item correlation tests in search of a common factor for dependence. Modeling the 
covariance across symptoms would ensure greater power for genetic analysis than the mere arbitrary 
summing of items allows. 
Low-frequency variants were predominantly highlighted in the GWAS (Study II) with smoking 
quantity and NW phenotypes. Owing to the Finnish population history and subsequent enrichment of 
rare genetic variation in the Finnish gene pool, many population-specific rare and low-frequency 
variants predisposing individuals to complex diseases and traits are likely to be found in Finns. 
Study III confirmed that a locus, 15q24-q25, harboring a gene cluster coding for nAChR subunits α5-
α3-β4 is a strong candidate to describe interindividual differences in smoking behavior that can be 
identified with the current gene mapping and association analyses methods. However, the effects of 
the variants on that locus are small and require large samples in order to emerge in statistical analyses 
as significant findings. 
It was also confirmed that nAChRs have pleiotropic effects. First, a novel association with alcohol 
use was detected with a variant residing on the CHRNA5-CHRNA3-CHRNB4 gene cluster on 15q25.1 
(Study III). The finding suggests that the effects of alcohol use may be mediated by nAChRs as one 
mechanism along with several others. Second, it was demonstrated that genetic variants on 15q25.1 
may contribute to higher BMI in never smokers and to lower BMI in current smokers (Study IV). The 
overall effect on BMI would have remained undiscovered with a traditional GWAS approach. Instead, 
this causality was revealed in a Mendelian Randomization study, which shows how stratification on 
established environmental factors with a known impact on traits and diseases may provide a means 
to unveil novel genetic factors that increase the risk of an outcome. However, Mendelian 
Randomization requires notably large samples to be capable of detecting causality. 
Despite all the global effort and time invested in several attempts to identify and characterize the 
secrets of the human genome, we are barely on the verge of starting to understand its many whimsical 
functions. The same applies to every complex trait and disorder, including smoking behavior and ND 
– the genetic architecture remains scarce and requires innovative leaps in technical development, a 
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higher capacity in progressing and analyzing gigantic data sets, along with better storage solutions 
for the rest of the genetic factors to become visible. 
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